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ABSTRACT 
 
Fyn, a member of the Src family kinases (SFK), is an oncogene in murine 
epidermis and is associated with cell-cell adhesion turnover and migration.  Additionally, 
Fyn is upregulated in multiple tumor types, including human cutaneous squamous cell 
carcinoma (cSCC).  Introduction of active H-Ras(G12V) into the HaCaT human 
keratinocyte cell line resulted in upregulation of FYN mRNA (200-fold) and protein, but 
did not increase the expression of other SFKs.  Using luciferase reporter constructs, we 
identified two nucleotides 74 bases upstream of the human FYN gene transcription start 
site as necessary for FYN upregulation in HaCaT-Ras cells.  Following chromatin 
immunoprecipitation and electrophoretic mobility shift assays, Lef-1 was identified as the 
transcription factor most likely binding to this site and mediating FYN upregulation.     
Increased Fyn expression levels following either the transduction of active Ras 
(HaCaT-Ras) or Fyn (HaCaT-Fyn) into HaCaT cells induced an epithelial-to-
mesenchymal transition (EMT), including loss of E-cadherin and cytokeratin expression, 
gain of vimentin expression and reduced cell-cell adhesion.  Introduction of Ras or Fyn 
also resulted in upregulation of the EMT master regulator, TWIST1, demonstrating a 
potential mechanism driving the transition to a mesenchymal phenotype.  The 
identification of EMT markers in cSCC significantly increases the risk of cancer-related 
  
xv 
 
mortality.  Therefore we next chose to inhibit Fyn activity to see if this would reverse or 
block these characteristics that result in clinically more dangerous cSCCs.   
Inhibition of Fyn activity using the clinical SFK inhibitor Dasatinib did not reduce 
cell viability, proliferation, apoptosis or autophagy in the transformed HaCaT-Ras cells 
when compared to the parental HaCaT cells.  However, Fyn inhibition using siRNA or 
Dasatinib increased cell-cell adhesion in HaCaT-Ras cells over 6-fold (p<0.001) through 
a rapid (5-60 min.) increase in the cortical F-actin cytoskeleton.  Treatment of the 
HaCaT-Fyn cells with Dasatinib also resulted in upregulation of F-actin.  Dasatinib did 
not restore cytokeratin expression, but induced F-actin colocalized with the adherens 
junction proteins α-catenin, β-catenin and p120catenin in HaCaT-Ras cells, suggesting 
that stable adherens junctions were mediating the increase in cell-cell adhesion.  
Additionally, Dasatinib treatment significantly inhibited cell migration (p<0.001).  
Inhibition of the Rho effector protein Rho-associated protein kinase (ROCK) blocked 
Dasatinib-induced F-actin and cell-cell adhesion (p<0.001) in HaCaT-Fyn and HaCaT-
Ras cells, implicating relief of Rho GTPase inhibition as a mechanism of Dasatinib-
induced cell-cell adhesion.  The ability of Dasatinib to promote F-actin polymerization 
was a key initiator of cell-cell adhesion, as Dasatinib-induced cell-cell adhesion was 
blocked by Cytochalasin D (p<0.001).  Conversely, inhibiting cell-cell adhesion with low 
Ca+2 media did not block Dasatinib-induced F-actin induction.  
Finally, topical Dasatinib treatment immediately following UV exposure 
significantly reduced total tumor burden in the SKH1 mouse model of skin 
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carcinogenesis (p<0.05).  Together these results identify the promotion of actin-based 
cell-cell adhesion as a newly described mechanism of action for Dasatinib and suggest 
that Fyn inhibition may be an effective therapeutic approach in treating SCC. 
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CHAPTER I 
INTRODUCTION 
 
1.1 The Human Skin 
 
The main function of the skin is to form a first line of defense, protecting the internal 
structures of an organism from external insults by creating a physical, antimicrobial and 
immunological barrier (Madison, 2003, Proksch, Brandner and Jensen, 2008).  In order to 
protect the organism, the skin must prevent excessive water loss, participate in 
thermoregulation and sensory perception and prevent damage induced by ultraviolet 
radiation, toxins, pathogens and physical trauma (Madison, 2003).  These functions of the 
skin are accomplished due to the unique anatomy of the dermis and epidermis.   
 
1.1.1 The Anatomy of the Skin 
 
The skin is composed of two main layers, the epidermis and the dermis.  More 
specifically, the epidermis makes up the outermost layer of the skin, creating a protective 
barrier composed primarily of keratinocytes at varying stages of differentiation (Proksch, 
Brandner and Jensen, 2008).  Separating the epidermis from the dermis is the basement 
membrane, a fibrous sheet composed of the basal and reticular laminae that creates a 
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surface for the epidermal cells to attach to, as well as a physical barrier against invading 
pathogens or malignant cells (Figure 1)(Paulsson, 1992, Liotta et al, 1980).  The dermis, 
in turn, is composed of connective and adipose tissue, as well as hair follicles, sweat 
glands, sebaceous glands, apocrine glands, lymphatic and blood vessels (Pearce and 
Grimmer, 1972).  The dermis protects internal structures from external stress, as well as 
provides tensile strength to the skin (Figure 1) (Pearce and Grimmer, 1972).  Although 
not technically considered a layer of the skin, the hypodermis lies underneath the dermis, 
aids in the attachment of the skin to the muscle and bone and is comprised mostly of 
adipose tissue.   
 
The epidermis is classified as a stratified squamous epithelium, meaning it is composed 
of several layers of epithelial keratinocytes undergoing a programmed process of 
squamous differentiation (Fuchs, 2008, Presland and Dale, 2000).  The surface layer of 
the epidermis is the stratum corneum, and is composed completely of fully differentiated, 
anuclear corneocytes (also known as squames).  The stratum corneum creates the most 
important barrier against water loss and external infiltration, although loss of this layer is 
not life-threatening (Proksch, Brandner and Jensen, 2008, Elias, Fritsch and Epstein, 
1977, Madison, 2003).  Underneath the stratum corneum is the stratum lucidum, an area 
of transition between the dead and living layers of the epidermis (Eckert and Rorke, 
1989).  Next is the stratum granulosum, where the keratinocytes lose their nuclei (as well 
as other intracellular organelles) and synthesize lipids to aid in the formation of a lipid 
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barrier (Eckert and Rorke, 1989, Eckert, 1989).  Following the stratum granulosum is the 
stratum spinosum, characterized by the formation of desmosomes between adjacent 
keratinocytes that give the layer a “spinous” appearance (Eckert, 1989).  This is also the 
layer where the keratinocytes begin production of suprabasal keratins K1 and K10, 
important intermediate filament proteins that aid in the cell’s tensile strength, as well as 
many signaling mechanisms (Dotto, 1999).  Finally, adjacent to the basement membrane 
is the stratum basale, a layer of keratinocytes that attach to the basement membrane using 
hemidesmosomes and proliferate to renew the stem cell pool or yield transit amplifying 
cells (Nie, Fu and Han, 2013).  These transit amplifying cells may also proliferate, but 
they ultimately begin to differentiate and progress through the overlying epidermal layers 
(Figure 1)(Houben, De Paepe and Rogiers, 2007, Allen and Potten, 1974, Ghazizadeh 
and Taichman, 2005).   
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Figure 1: Histology of the Epidermis 
A section of the human epidermis stain with Hematoxylin and Eosin is pictured.  
The Dermis and four layers of the Epidermis are labeled (Stratum Corneum, 
Stratum Granulosum, Stratum Spinosum, Stratum Basale), as well as the 
basement membrane.  Picture of skin histology courtesy of Mitchell F. Denning.    
Dermis 
Basement  
Membrane 
Stratum Basale 
Stratum Spinosum 
Stratum Corneum 
Stratum Granulosum 
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Although the layers of the epidermis are clearly defined and identifiable microscopically, 
they are in constant flux.  As the stem cells proliferate at the stratum basale, they yield 
transit amplifying cells whose daughter cells are eventually pushed up from the basement 
membrane, decreasing their cell-matrix adhesion by downregulating their 
hemidesmosomes in favor of cell-cell adhesion complexes such as desmosomes and 
adherens junctions (Dotto, 1999).  The increase in cell-cell adhesion complexes is aided 
by an increasing gradient of extracellular Ca+2 from the stratum spinosum to the stratum 
granulosum, a driving force in keratinocyte differentiation (Tu et al, 2004, Menon et al, 
1992, Forslind et al, 1997).  Extracellular Ca+2 binds to its surface receptor CaR, 
activating phospholipase C to induce inositol 3 phosphate and diacyl glycerol production, 
increasing intracellular Ca+2 and activating protein kinase C family members, including 
PKC-α, -δ and –η, to induce cellular differentiation pathways (Dotto, 1999, Denning et 
al, 1995, Lee et al, 1997, Osada et al, 1993, Tu et al, 2004).   Other groups have also 
shown the importance of retinoic acid and Vitamin D3 in regulating the expression of 
pro-differentiation factors (Dotto, 1999).  As the cells differentiate, they lose their ability 
to proliferate and begin to express markers such as keratin 1 and 10, involucrin, filaggrin 
and transglutaminase (Eckert and Rorke, 1989, Dotto, 1999).  During differentiation the 
keratinocytes continue to move through the stratum spinosum to the stratum granulosum 
where they lose their nuclei to create a tightly bound layer of corneocytes, the outer 
layers of which can be shed to protect the integrity of the organ.  When this carefully 
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regulated program of differentiation is disturbed the barrier function of the skin is 
compromised (Eckert and Rorke, 1989).   
 
1.1.2 Skin Cancer Diagnoses and Prevalence  
 
Three main classes of malignancies arise from cells of the epidermis: melanoma, basal 
cell carcinoma (BCC) and squamous cell carcinoma (cSCC).  Over 3.5 million cases of 
skin cancer were diagnosed in the United States of America in 2010, making non-
melanoma skin cancers more common than all other forms of cancer combined (Perera 
and Sinclair, 2013, Rogers et al, 2010a).  Rates of diagnoses for non-melanoma skin 
cancer have been increasing 3-8% per year since the 1960s, most likely due to increased 
ultraviolet light (UV) exposure, changes in outdoor activities and clothing styles, 
increased lifespan and ozone depletion (Gloster and Brodland, 1996, Green, 1992).  
Current studies have shown an even greater increase (around 300%) in diagnosis rates 
since 1994 (Perera and Sinclair, 2013, Rogers et al, 2010b).  BCCs are histologically very 
uniform and homogenous tumors, and are also extremely common.  3 out of 10 
Caucasians will develop a BCC within their lifetime (Bhawan, 2007, Ratushny et al, 
2012).  Approximately 20% of non-melanoma skin cancers are cSCCs, and these tumors 
are differentiated from BCCs by the presence of keratin pearls and other indicators of 
stratification (Diepgen and Mahler, 2002).  99% of cSCC cases are successfully treated 
with surgical excision (LeBoeuf and Schmults, 2011, Newman, 1991, Clayman et al, 
2005).  Melanoma originates from the pigment producing melanocytes and is the least 
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common type of skin cancer, with 18-20x lower rates of diagnosis than BCC and cSCC 
(Diepgen and Mahler, 2002).   However, melanoma is the most aggressive and most fatal 
form of skin cancer, causing 75% of skin cancer-related deaths (Jerant et al, 2000).   
 
1.2 Cutaneous Squamous Cell Carcinoma (cSCC) 
 
When keratinocytes from the epidermis undergo malignant transformation and 
histologically maintain characteristics of squamous differentiation, a tumor classified as a 
cSCC results.  UV exposure, especially UVB, is the most common carcinogen driving the 
formation of cSCCs (Alam and Ratner, 2001).  Additionally, many skin lesions are 
diagnosed in the precursor phase of cSCC or as an actinic keratosis (AK).  Once the 
malignancy has progressed to the diagnosis of cSCC it is classified as either cSCC in situ 
(also known as Bowen’s disease), or as invasive SCC (Figure 2)(Croxton, Ma and Cress, 
2002).     
 
1.2.1 Actinic Keratoses (AKs) 
 
AKs are often considered precursor lesions for cSCC and are defined as epidermal 
dysplasia with enlarged, irregular and hyperchromatic nuclei and disorganized growth 
and differentiation resulting in a thickened stratum corneum with retained nuclei 
(Ratushny et al, 2012, Butani, Arbesfeld and Schwartz, 2005).  The atypia that 
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characterizes AKs does not penetrate the full thickness of the epidermis – instead it is 
usually confined to the deeper layers of the epidermis with overlying parakeratotic and 
hyperkeratotic cells (Figure 2)(Anwar et al, 2004).  15-20% of AKs progress to cSCCs 
within 10-25 years (Marks, Rennie and Selwood, 1988).  Because most patients present 
with an average of 6-8 AK lesions, their risk of developing invasive SCC within one year 
is between 0.15% and 80%.  However, within one year AKs have a 26% likelihood of 
spontaneous regression (Ratushny et al, 2012).   
 
1.2.2 cSCC in situ 
 
cSCC in situ is often the next step in malignant progression from AKs, where a greater 
degree of atypia is observed but the abnormal cells have not invaded the basement 
membrane (Ratushny et al, 2012, Bhawan, 2007).  More specifically, the atypia of cSCC 
in situ is seen through all layers of the epidermis, while the atypia of AKs are contained 
to fewer layers (Figure 2)(Butani, Arbesfeld and Schwartz, 2005).  Other lesions that fall 
underneath the subheading of cSCC in situ include Bowen’s disease, arsenical keratosis, 
bowenoid papulosis and erythroplasia of Queyrat (Ratushny et al, 2012, Bhawan, 2007, 
Anwar et al, 2004).  Some dermatologists also consider AKs to be cSCC in situ, as 
clinical criteria to differentiate AKs from cSCC have not been determined (Bhawan, 
2007, Moy, 2000).  Histologically this malignancy is defined as transepidermal atypia 
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with loss of polarity, mitotic figures, dyskeratosis, hyperchromasia, abnormal 
differentiation and nuclear crowding (Bhawan, 2007).   
 
1.2.3 Invasive cSCCs 
 
Once malignant keratinocytes have invaded past the basement membrane and into the 
dermis they are no longer considered cSCC in situ and are instead histologically 
classified as invasive cSCCs (Figure 2)(Mullen et al, 2006).  Clinically, the identification 
of invasion or a migratory capacity in cSCC decreases the average predicted three year 
disease free survival rate by thirty percent (Clayman et al, 2005).  cSCCs most likely to 
metastasize fulfill the following clinical parameters: larger than 2 cm, invade more than 6 
cm, poorly differentiated, have undergone previous treatment or are located near the 
nose, ear or lip (Salasche, 2000, Mullen et al, 2006).   
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Figure 2: Progression of a cSCC 
cSCCs often develop in a stepwise manner, beginning with an initial mutation that 
is often induced by damage from UV exposure.  This mutation confers either a 
growth or survival advantage, resulting in the development of a patch of 
keratinocytes containing this mutation.  The lesion is diagnosed as an actinic 
keratosis when it has histological features such as hyperchromatic nuclei, as well 
as abnormal proliferation or differentiation.  However, this atypia does not 
penetrate the full thickness of the epidermis.  Once this atypia does penetrate the 
entire thickness of the epidermis the lesion is characterized as cSCC in situ.  
Further progression and the acquisition of a migratory phenotype, as well as 
penetration of the basement membrane, results in a diagnosis of invasive cSCC.   
 
  
 
11 
 
 
 
1.2.4 Causes of cSCC 
 
Because the skin is the main mechanism of defense against external insults, it is exposed 
to a high level of external injury, either physically or through mutagens.  Risk factors for 
cSCC include: therapy with methoxsalen and UVA radiation, exposure to ionizing 
radiation, infection with human papillomavirus, exposure to chemical carcinogens (ex. 
arsenic, polycyclic hydrocarbons), immunosuppression, organ transplantation, leukemia 
and lymphoma, chronically injured or diseased skin, ulcers, osteomyelitis and radiation 
dermatitis (Alam and Ratner, 2001).  Increased risk of cSCC is also associated with 
certain genetic disorders such as genodermatosis, oculocutaneous albinism, xeroderma 
pigmentosum, Ferguson-Smith Syndrome, Rothmund-Thomson Syndrome, Fanconi 
anemia, epidermodysplasia verruciformis, dyskeratosis congenita, Bloom syndrome, 
Werner syndrome and chronic inflammatory disorders such as dystrophic epidermolysis 
bullosa (Nikolaou, Stratigos and Tsao, 2012, Alam and Ratner, 2001).   
 
However, the most common cause of cSCC is exposure to ultraviolet radiation, especially 
UVB and to a lesser extent UVA, two carcinogens considered responsible for 90% of 
skin cancers (Rogers et al, 2010b, Alam and Ratner, 2001).  A patient’s photosensitivity 
or risk of cSCC following UV exposure is clinically assessed using the Fitzpatrick Scale.  
For example, the highest risk patients have very pale skin with blond or red hair, blue 
eyes, freckles and they always burn and rarely tan (Ravnbak, 2010).  Exposure to the 
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damaging rays of sunlight results in the formation of pyrimidine dimers, adducts in the 
DNA that can result in DNA mutation following replication or during repair (Melnikova 
and Ananthaswamy, 2005).  Ozone depletion has played a major role in the increased 
skin cancer diagnosis rate due to an increased exposure to UV rays.  A 2% depletion in 
ozone concentration was calculated to cause a 6-12% increase in non-melanoma skin 
cancer (Kripke, 1988, Kelfkens, de Gruijl and van der Leun, 1990).  However, during the 
winter and spring months the ozone layer has been shown to decline 10-40% over the 
northern hemisphere, causing a predicted 20-60% increase in UV exposure and a 40-
120% increase in non-melanoma skin cancer occurrence (Oikarinen and Raitio, 2000).  
Increased use of tanning beds is also increasing the rate of cSCC diagnosis, particularly 
in young patients that regularly use tanning beds (International Agency for Research on 
Cancer Working Group on artificial ultraviolet (UV) light and skin cancer, 2007).  
Additionally, the risk of cSCC due to immunosuppression is growing.  One year 
following renal transplant the risk of cSCC increases 7%, 45% following 11 years and 
70% following 20 years of immunosuppression (Bouwes Bavinck et al, 1996).  
Pharmacological therapies, for example sorafenib treatment for renal cell carcinoma or 
BRAF inhibitors, have also been linked to an increased incidence of AKs and cSCCs 
(Smith et al, 2009, Robert, Arnault and Mateus, 2011). 
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1.2.5 Pathogenesis of cSCCs 
 
The formation of cSCCs is a multistep process, requiring the mutation of several 
oncogenes and tumor suppressor genes (Xie and Bikle, 2007).  Following chronic 
exposure to a mutagen (usually UV exposure), the DNA of a keratinocyte undergoes 
significant damage (Alam and Ratner, 2001).  In fact, normal-appearing, sun exposed 
skin contains thousands of loss-of-function mutations in the most common cSCC tumor 
suppressor, p53 (Nakazawa et al, 1994, Jonason et al, 1996a, Campbell et al, 1993, Xie 
and Bikle, 2007).  Keratinocytes containing this initial mutation have a growth 
advantage, as loss of p53 function prevents cell cycle arrest and apoptosis following 
DNA damage.  Through this mechanism patches of mutant keratinocytes form, creating 
cell populations at increased risk of a secondary mutation following chronic UV exposure 
(Melnikova and Ananthaswamy, 2005, Jonason et al, 1996b).  Abnormal cell growth, in 
turn, results in epidermal dysplasia and the formation of a precursor AK lesion 
(Melnikova and Ananthaswamy, 2005).  Loss of p53 function is found in over 50% of 
human cancers (Hollstein et al, 1991).  Upon UV exposure p53-/- and p53+/- mice 
develop AKs and cSCCs more rapidly than wild type mice, reaffirming this tumor 
suppressor’s role in epidermal carcinogenesis (Jiang et al, 1999).  Loss of chromosome 
9p21 is another common genetic alteration, resulting in loss of p16INK4 and p14ARF, 
two regulators of p53 (Xie and Bikle, 2007).  Mutations in p16 promote increased 
progression through the cell cycle and an increased risk of genetic mutations due to errors 
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in mitosis (Xie and Bikle, 2007).  Upregulation of the Fas receptor in keratinocytes is 
another common cause of cSCC, reducing the cell’s ability to regulate apoptosis 
(Melnikova and Ananthaswamy, 2005).  Other mutations often seen in cSCC involve c-
Myc over-expression and activation of STAT signaling, resulting in tumor angiogenesis 
and cytokine secretion, respectively (Xie and Bikle, 2007).  Mutations in H-Ras or N-Ras 
are observed in 30-50% of human cSCCs, with H-Ras being the most commonly mutated 
Ras isoform (Xie and Bikle, 2007, Boukamp, 2005).  Increased levels of Src family 
kinases (SFKs), EGFR and ATF-3 have also been associated with cSCC, as has increased 
PI3K/Akt activity (Kim et al, 2011, Lentini et al, 2006, Toll et al, 2009, Toll et al, 2010, 
Sekulic et al, 2010).  Additionally, increased Fyn activity has been shown to 
downregulate p53 activity, increasing the malignant transformation of keratinocytes 
(Zhao et al, 2009).   
 
1.3 Ras Oncogene 
 
Ras proteins are a member of the RAS-like GTPase family that, in response to external 
stimuli, alter signaling pathways associated with growth, migration, adhesion, 
cytoskeletal maintenance, survival and differentiation (Rajalingam et al, 2007).  The Ras-
like GTPase superfamily has been broken down into five subfamilies of GTPases, 
including Ras, Rho, Rab, Arf and Gα subunits of heterotrimeric G-proteins.  The Ras 
subfamily, in turn, includes Ras, Rap, Ral and Rheb, among others (Colicelli, 2004).   
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1.3.1 Ras Structure  
 
A high degree of sequence homology exists between H-, N- and K-Ras, with the majority 
of variability occurring in the C-terminal hypervariable region.  This C-terminal region is 
the site of posttranslational modifications that allow the protein to anchor at the plasma 
membrane and aid in intercellular trafficking to the cytoplasmic membrane (Hancock and 
Parton, 2005).  Ras also contains a G domain that regulates binding to GDP/GTP, and 
mutations in this sequence can turn Ras permanently off or on, depending on whether 
binding or hydrolysis of GTP is blocked (Vetter and Wittinghofer, 2001). 
 
1.3.2 Regulation of Ras Signaling 
 
Ras is classified as a GTPase, thus the activity of Ras is dependent on whether it is bound 
to GTP (protein is active or “on”) or GDP (protein is inactive or “off”).  Although Ras 
does have a small amount of intrinsic GTPase function, Ras activity is most often 
regulated by other GTPase activating proteins (GAPs) and guanine nucleotide exchange 
factors (GEFs).  Following posttranslational modification in the endoplasmic reticulum, 
Ras is trafficked to the cytoplasmic membrane, where it is activated in response to 
external signals (Rajalingam et al, 2007).  For example, following activation of the 
epidermal growth factor receptor (EGFR), the receptor binds to GRB2 to recruit SOS1 or 
SOS2, two Ras-GEFs that exchange the Ras-bound GDP for GTP, activating Ras to alter 
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intracellular signaling pathways (Downward, 2003).  Downregulation of Ras signaling 
requires the activity of Ras-GAPs to hydrolyze GTP to GDP, and alteration in Ras-GAP 
activity, localization, expression or ability to bind Ras can result in constitutively active 
Ras (Grewal et al, 2011). 
 
1.3.3 Signaling Downstream of Ras  
 
Increased Ras activity results in the activation of several signaling cascades.  Following 
activation by external growth factors, Ras binds to and activates Raf, ultimately 
upregulating the MEK/MAPK pathway and altering gene transcription to hasten cell 
cycle progression and increase cell survival (Rajalingam et al, 2007, Downward, 2003).  
Ras also activates PI3K to induce the Akt signaling pathway, promoting cell proliferation 
and survival (Rajalingam et al, 2007).  PI3K can directly bind to and activate Rac, a Rho 
family protein that regulates the stability of the actin cytoskeleton and the migratory 
capacity of the cell (Downward, 2003).   
 
1.3.4 Ras as an Oncogene 
 
Studies have shown that at least one Ras gene contains an activating mutation in 
approximately 20% of human cancers (Rajalingam et al, 2007, Downward, 2003).  
Mutations resulting in oncogenic Ras activity occur primarily at G12, G13 and Q61, 
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preventing GTP hydrolysis to generate constitutively active Ras (Barbacid, 1987).  
Additionally, Ras activity is upregulated in tumors without direct Ras mutations due to 
activating mutations upstream of Ras or loss of GAP expression, increasing Ras 
signaling.  Increased Ras activity results in the dysregulation of signaling pathways 
governing cell growth, programmed cell death, invasiveness and angiogenesis 
(Downward, 2003).   
 
1.3.5 Ras in the Epidermis 
 
The three isoforms of Ras are differentially expressed in different tissue systems.  H-Ras 
is primarily expressed in brain, muscle and skin, while K-Ras is expressed in gut, lung 
and thymus and N-Ras is expressed in the testis and thymus (Rajalingam et al, 2007).  
Genetic studies of knockout mice indicate that loss of H-Ras and N-Ras do not alter 
mouse development or tissue homeostasis, while loss of K-Ras is not compatible with life 
(Umanoff et al, 1995, Esteban et al, 2001, Johnson et al, 1997).  However, expression of 
H-Ras from the K-Ras locus rescues mouse development, suggesting that the distribution 
of tissue expression is more important than specific differences between Ras isoforms 
(Drosten, Lechuga and Barbacid, 2013a).   
 
In the epidermis, Ras has been shown to induce cellular proliferation and inhibit 
differentiation (Dajee et al, 2002, Drosten, Lechuga and Barbacid, 2013b).  Interference 
18 
 
 
 
with all three Ras isoforms in the basal layer of keratinocytes results in epidermal 
thinning and hyperkeratosis, indicating a decrease in keratinocyte proliferation (Dajee et 
al, 2002).  Loss of Ras signaling in vitro has also been shown to induce downregulation 
of c-Myc and ΔNp63 (an isoform expressed from the p63 locus), regulators of 
proliferation, as well as upregulation of p21 and p15, two proteins involved in cell cycle 
arrest (Drosten, Lechuga and Barbacid, 2013a).  Additionally, increased Ras activity in 
the basal layer of mouse keratinocytes inhibits cellular differentiation and increases 
proliferation to induce the formation of cSCCs (Vitale-Cross et al, 2004, Khavari and 
Rinn, 2007).  Overall, changes in Ras signaling alter the proliferation and differentiation 
programs of keratinocytes, two changes that increase the likelihood of cSCC formation 
(Drosten, Lechuga and Barbacid, 2013b). Thus it is clear that Ras is an important 
oncogene in the formation of cSCC.   
 
1.3.6 Ras and cSCC 
 
22% of cSCCs contain mutations in at least one Ras gene, most commonly in the H-Ras 
isoform.  Chemical carcinogenesis using DMBA/TPA is a common method of cSCC 
induction in the lab.  DMBA is applied to the skin, causing a mutation in Ras, and then 
TPA is applied to promote the formation of the tumor (Brown, Buchmann and Balmain, 
1990).  Expression of constitutively active H-Ras or K-Ras in a murine epidermis 
resulted in the formation of papillomas that progress to cSCCs, suggesting that abnormal 
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Ras activity is sufficient to cause skin carcinogenesis.  However, expression of 
constitutively active H-Ras at endogenous levels was not sufficient to induce papilloma 
formation, indicating that a threshold of Ras expression must be surpassed to induce skin 
tumors (Drosten, Lechuga and Barbacid, 2013b).  Additionally, tumor promotion in the 
epidermis of H-Ras knockout mice resulted in fewer papillomas than in wild type mice 
(Ise et al, 2000).  Thus, alterations in Ras activity levels play an important role in 
keratinocyte transformation and skin carcinogenesis.   
 
Adhesion complexes between cells serve as major hubs of signaling in the epidermis and 
changes in signaling at these locations can alter Ras activity.  Components of both the 
adherens junction and desmosome inhibit signaling from EGFR to induce growth arrest, 
and downregulation of these complexes following oncogenic transformation results in 
sustained activation of Ras signaling pathways.  During the epithelial to mesenchymal 
transition (EMT) the stability of these junctions is downregulated, resulting in 
upregulation of Ras signaling and cellular transformation (Kern, Niault and Baccarini, 
2011).   
 
1.4 Src Family Kinases (SFKs) 
  
In 1911 Peyton Rous discovered that injecting tissue homogenate from a spindle cell 
sarcoma he isolated from a chicken’s breast into the breast of a healthy chicken resulted 
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in tumor formation in the second animal.  This occurred whether the injection contained 
whole cells, desiccated or glycerinated preparations of dead tumor cells or cell free 
filtrates (Saito et al, 2010, Guarino, 2010).  Although Rous believed he had discovered 
evidence that all tumors were a result of viral infection, he had actually discovered a 
mutant form of the first known tyrosine kinase, Src (Guarino, 2010).  For these 
discoveries Peyton Rous was awarded the Nobel Prize in 1966, and in 1989 J. Michael 
Bishop and Harold Varmus won the Nobel Prize for identifying the ability of an active 
form of c-Src to drive a cancerous phenotype, beginning the field of oncogenesis (Saito et 
al, 2010).   
 
Clearly, Src has played an important role in our growing understanding of tumorigenesis 
and cancer biology.  Since the identification of Src, other closely related proteins have 
been identified and added to the Src family.  These kinases include Fyn, Lyn, Yes, Blk, 
Lck, Hck, Fgr and Yrk (Varkaris et al, 2014).  Src, Yes and Fyn are highly expressed in 
platelets, neurons, osteoclasts and epithelial tissues and are ubiquitously expressed in 
other tissues, while the other SFKs are expressed mainly in hematopoietic cells (Thomas 
and Brugge, 1997, Guarino, 2010).   
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Figure 3: Dendogram of Src Family Kinase Members 
This figure demonstrates the relationship between different members of the Src 
family of protein tyrosine kinases.  
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1.4.1 Structure of SFKs 
 
The protein structure of all SFKs is highly redundant, resulting in a great deal of 
functional overlap between family members.  From the N- to C- terminal SFKs are 
composed of an SH4 domain that is myristoylated (and sometimes palmitoylated) to aid 
in association with the cell membrane, a unique domain specific to each SFK member 
that directs protein-protein binding, an SH3 domain that binds to proteins with PXXP-
like sequences (left-handed polyproline type II sequence motifs), an SH2 domain that 
binds proteins with phosphotyrosine resides in a pYEE1 sequence, an SH2-kinase linker 
domain, an SH1 catalytic or kinase domain and a C-terminal regulatory element (Saito et 
al, 2010).  The SH1 domain is composed of two lobes, a small N-terminal lobe that binds 
ATP and the protein substrate to allow phosphotransfer and a larger C-terminal lobe that 
controls accessibility to substrates (Saito et al, 2010, Guarino, 2010, Schenone et al, 
2011).   
 
1.4.2 Regulation of SFK Signaling  
 
SFK activity is regulated by tyrosine phosphorylation of two tyrosines, commonly 
referred to by their location within the Src protein.  These two sites are Y416 (activating) 
and Y528 (inhibitory).  Phosphorylation of Y528 within the C-terminal regulatory 
element creates a binding site for the SH2 domain, inhibiting substrate binding.  This also 
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allows the SH2-linker domain to bind to the backside of the SH1 catalytic domain, 
creating a polyproline type II helix conformation that can bind to the SH3 domain 
(Brignatz et al, 2009).  Ultimately, these conformational changes result in autoinhibition 
of SFK activity by preventing substrate binding, inhibiting kinase activity and masking 
the activating Y416 site.  However, other proteins containing phosphotyrosine or 
polyproline helices can compete for the SH2 or SH3 domain, unfolding SFKs from their 
inhibitory conformation.  Once this conformational change has occurred, SFKs can 
autophosphorylate Y416, resulting in displacement the SH2-kinase linker domain from 
the SH1 catalytic domain and full kinase activity (Brignatz et al, 2009, Saito et al, 2010, 
Bjorge, Jakymiw and Fujita, 2000, Li et al, 2005).   
 
Although SFK activity can be regulated by autophosphorylation of Y416 and Y528, 
association with specific proteins can contribute to SFK activity through their kinase or 
phosphatase activities (Li et al, 2005, Rengifo-Cam et al, 2004).  For example, Srcasm 
contains optimal ligands for both the SH2 and SH3 domains of SFKs, inducing their 
activity.  However, Srcasm’s role in SFK activity is more complex, as results show that 
Srcasm in fact acts like a rheostat to regulate SFK activity, activating or repressing the 
SFK based on the ratio of SFK and Srcasm levels in the cell (Li et al, 2005, Li et al, 
2007).  Csk is an inhibitory protein that is often found in near SFKs and can 
phosphorylate Y528 to induce autoinhibition (Shima, Nada and Okada, 2003, Bjorge, 
Jakymiw and Fujita, 2000).  SFKs can also be activated by protein tyrosine phosphatases 
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such as PTPalpha, PTPgamma, SHP-1, SHP-2 and PTP1B that remove the inhibitory 
Y527 phosphorylation mark (Frame, 2002).  
 
1.4.3 Signaling Downstream of SFKs 
 
SFK signaling has been implicated in a large array of pathways, including those that 
govern cell metabolism, viability, proliferation, angiogenesis, differentiation and 
migration (Ingley, 2008, Okada, 2012).  Src recruits members of the Gab/IRS family to 
activate PI3K and ultimately Akt, altering the cell’s metabolism, gene transcription, 
migration and survival (Frame, 2002, Sirvent, Benistant and Roche, 2012).  Increased Src 
activity activates the PI3K and Ras/MEK pathways to suppress p27 and increase 
CyclinD, CyclinE and CyclinA to speed progression through the cell cycle (Frame, 
2002).  SFKs directly phosphorylate and activate the transcription factor STAT3 to 
increase cell growth (Sirvent, Benistant and Roche, 2012).  SFKs also increase the 
expression of pro-angiogenic factors such as VEGF, matrix metalloproteases and 
interleukin-8.  Src reduces the stability of focal adhesions by phosphorylating integrin 
subunits, inhibiting RhoA and activating FAK, Ras and phosphatidylinositol phosphate 
kinase (Kim, Song and Haura, 2009, Zhang and Yu, 2012).  Furthermore, Src activity is 
associated with downregulation of E-cadherin synthesis and stability at the cytoplasmic 
membrane through phosphorylation of p130catenin and FAK (Kim, Song and Haura, 
2009).  Overall, these signaling changes result in decreased cell adhesion, increased 
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migration, decreased apoptosis, increased proliferation and increased angiogenesis, all of 
which promote cellular transformation and tumorigenesis (Frame, 2002, Guarino, 2010).    
 
1.4.4 SFKs in the Epidermis 
 
Two major, yet contradictory, roles have been ascribed to SFKs in the epidermis 
(Avizienyte and Frame, 2005).  During keratinocyte differentiation and stratification, 
elevated extracellular Ca+2 induces the formation of adherens junctions, initiating 
signaling cascades necessary for cell polarization and desmosome formation.  Tyrosine 
phosphorylation by SFKs is necessary for this initial assembly of the adherens junction 
structure (Calautti et al, 1998).  Therefore, one of the most important functions of the 
SFKs in the epidermis is the assembly of adhesion structures to aid in keratinocyte 
differentiation.  Contradictory to this, SFKs have also been implicated in the dissolution 
of epidermal junctions, as the stability of adherens junctions in vitro increases upon 
inhibition of SFK activity (Owens et al, 2000).  Supporting Src’s pro-migratory role, 
staining for active SFKs revealed increased activity in skin samples from patients 
suffering from psoriasis, AKs, cSCC in situ and cSCCs when compared to adjacent skin, 
most likely due to aberrant activation of EGFR (Ayli et al, 2008).  
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1.4.5 Prevalence of SFK Activity in cSCC 
 
Somatic mutations in SFKs have only been recorded in a study of human colorectal 
cancer (Irby et al, 1999).  Despite the rarity of SFK mutations in human cancers, most 
solid tumors have increased SFK activity, and this upregulation often correlates with 
advanced disease progression (Varkaris et al, 2014, Yeatman, 2004, Frame, 2004, 
Mandal et al, 2008).  More specifically, Src over-expression or activation has been 
identified in head and neck, breast, colon, bladder, stomach, ovary, lung, prostate, 
glioma, melanoma and pancreatic tumors, among others (Matsumoto et al, 2004, 
Guarino, 2010).  Increased SFK activity has also been detected in human cSCC tumors 
when compared to adjacent skin samples (Lee et al, 2010). SFK activity is frequently 
upregulated following alterations in one of its upstream activators such as PDGFR, 
EGFR or FGFR, reversing the inhibitory conformation of the SFKs to induce their 
activity (Okada, 2012, Bromann, Korkaya and Courtneidge, 2004).  The introduction of 
constitutively active Src to the basal keratinocytes of the murine epidermis resulted in 
severe epidermal hyperplasia and death within three weeks of birth.  Over-expression of 
wild type Src resulted in epidermal hyperplasia, spontaneous cSCCs and increased 
susceptibility to chemical carcinogenesis with increased risk of metastasis (Matsumoto et 
al, 2004).  Inhibition of SFK activity using AZD0530 during chemical carcinogenesis 
significantly reduced keratinocyte hyperproliferation and papilloma formation (Serrels et 
al, 2009).  Additionally, increased SFK activity through conditional knockout of the SFK 
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inhibitor Csk resulted in chronic inflammation and epithelial hyperplasia with 
disorganized keratinocyte stratification (Yagi et al, 2007).  Src function has also been 
identified as a driver of EMT in epithelial cells, a conversion associated with loss of cell-
cell adhesion (Avizienyte and Frame, 2005, Mandal et al, 2008).  Increased SFK activity 
in keratinocytes resulted in activation of Rac1, upregulation of Snail and Twist, as well as 
inhibition of RhoA, all drivers of EMT (Yagi et al, 2007).  Thus there is significant 
evidence suggesting that increased SFK activity plays an important role in keratinocyte 
malignancies.   
 
1.5 Fyn 
 
In 1986 Fyn was cloned based on its homology to the Src family kinase (SFK) member 
Yes (Semba et al, 1986, Davidson, Viallet and Veillette, 1994).  Fyn is a 59 kDa protein 
composed of 537 amino acids and the 200 kb gene coding for its expression is found on 
chromosome 6q21 (Saito et al, 2010).  Like its Src family members, Fyn tyrosine 
phosphorylates residues on target proteins in response to extracellular signals to alter 
gene regulation or induce changes in cell adhesion (Guarino, 2010).   
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1.5.1 Regulation of Fyn Expression  
 
Three isoforms of Fyn have been identified that differ in the SH2-linker region through 
alternative splicing of exon 7 (Brignatz et al, 2009, Goldsmith, Hall and Atkinson, 2002).  
Fyn(B) is predominantly expressed in the central nervous system and includes exon 7a, a 
region that is believed to have been derived through a recombinatorial event with another 
gene.  Fyn(T) is predominantly expressed in T-cells and contains exon 7b, a sequence 
that creates a smaller contact surface with the SH3 domain and therefore is less efficient 
at autoinhibition and more efficient at phosphorylating downstream targets and inducing 
cellular transformation.  FynΔ7, the third isoform, lacks exon 7 and is not translated to 
protein.  Despite the high levels of expression of Fyn(B) and Fyn(T) in neurons and T-
cells, respectively, both isoforms are ubiquitously expressed in other tissues (Brignatz et 
al, 2009, Goldsmith, Hall and Atkinson, 2002). 
 
Although Fyn is overexpressed in many cancers, detailed study of FYN regulation has 
only been undertaken in chronic myelogenous leukemia, where the oncogene Bcr-ABL 
drives reactive oxygen species production, activating the transcription factors Egr1 and 
Sp1 to upregulate FYN gene transcription (Saito et al, 2010, Zhao et al, 2009, Ban et al, 
2008, Lu et al, 2009, Posadas et al, 2009, Talantov et al, 2005, Gao et al, 2009).  Vipin 
Yadav from the Denning lab also found that in cSCC the introduction of constitutively 
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active H-Ras results in Fyn upregulation through a PI3K-Akt dependent mechanism 
(Yadav and Denning, 2011).   
 
1.5.2 Fyn in Keratinocyte Differentiation 
 
Fyn activity has been implicated in both KC differentiation and oncogenesis.  
Differentiation signals, such as activation of the Ca+2 receptor by extracellular Ca+2, 
induce Fyn activity and recruitment to the plasma membrane (Calautti et al, 1995, Tu et 
al, 2008).  Once localized to the membrane, Fyn phosphorylates tyrosines on members of 
the adherens junction to stabilize its formation (Tu et al, 2008, Calautti et al, 1998, 
Calautti et al, 2002, Tu, Chang and Bikle, 2011).  Following adhesion initiation, Fyn 
activates signaling cascades involving phospholipase C/PI3K/Akt and PKCη that 
ultimately induce KC differentiation (Tu et al, 2008, Cabodi et al, 2000).  Loss of Fyn 
expression in vivo alters the differentiation program, as primary KCs from Fyn -/- mice 
do not stratify in culture and express lower levels of the differentiation markers 
transglutaminase, keratin 1 and filaggrin (Ilic et al, 1997, Calautti et al, 1995).  The skin 
of Fyn -/- mice also expresses reduced levels of these markers and has impaired cell-cell 
junctions, particularly adherens junctions (Calautti et al, 1995, Calautti et al, 1998).  KCs 
from mice that overexpress Fyn have increased transglutaminase activity following Ca+2 
exposure, suggesting increased KC differentiation (Zhao et al, 2009, Cabodi et al, 2000, 
Li et al, 2007).  Taken together, these findings indicate that Fyn activity is involved in 
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KC differentiation, as this process is impaired upon loss of Fyn and increased with Fyn 
over-expression.    
 
   
1.5.3 Fyn in cSCC and Keratinocyte Oncogenesis (EMT) 
 
While Fyn is a participant in the KC differentiation program, Fyn activity has also been 
implicated in KC transformation and oncogenesis (Zhao et al, 2009, Calautti et al, 1995, 
Tu et al, 2008).  A survey of human cSCCs showed increased SFK expression through all 
layers of the tumors (Ayli et al, 2008).  Over-expression of constitutively active 
Fyn(Y528F) in murine epidermis using the Keratin 14 promoter resulted in the formation 
of keratotic tumors and actinic keratoses that progress to squamous cell carcinoma, most 
likely through Fyn-mediated downregulation of the tumor suppressors Notch1 and p53 
(Zhao et al, 2009).  Additionally, introduction of oncogenic H-Ras in the KC cell line 
HaCaT resulted in upregulation of Fyn expression via a PI3K/Akt signaling mechanism, 
increasing the migratory and invasive capacity of the cells (Yadav and Denning, 2011).  
Increased Fyn activity has also been associated with the epithelial to mesenchymal 
transition and migratory capacity of oral squamous cell carcinoma cell lines (Lewin et al, 
2010).   
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1.5.4 Fyn in Keratinocyte Adhesion  
 
Fyn’s function in both KC differentiation and transformation is strongly associated with 
its role in cellular adhesion.  To mediate KC differentiation, Fyn activity aids in the 
initiation and formation of cell-cell adhesions, while in oncogenesis Fyn aids in the 
dissolution of adhesions.  These opposing roles for Fyn in KC biology may at first appear 
contradictory, but a careful analysis of the literature suggests several possible 
mechanisms to integrate these divergent functions.     
 
1.5.4.1 Fyn’s Role at the Adherens Junction 
 
Once KCs leave the stratum basale, they maintain the integrity of the epidermis primarily 
through two cell-cell adhesion complexes, the adherens junction and the desmosome.  
Formation of an immature or transient adherens junction is initiated when E-cadherin 
proteins from adjacent cells bind homophilically through their extracellular domain.  
Following E-cadherin-mediated adhesion, p120catenin associates with the cadherin at its 
juxtamembrane domain (Grosheva et al, 2001, Mariner, Davis and Reynolds, 2004, 
Alema and Salvatore, 2007).  Fyn associates with the adherens junction by binding to 
p120catenin, where it phosphorylates several downstream targets, including β- and α-
catenin, to induce their association with the cadherin and increase the stability of the 
complex (Figure 4)(Tu et al, 2008, Calautti et al, 1998, Tu, Chang and Bikle, 2011, 
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Calautti et al, 2002, Grosheva et al, 2001, Piedra et al, 2003, Lilien and Balsamo, 2005, 
Lampugnani et al, 1997, Hu, O'Keefe and Rubenstein, 2001).  However, the adherens 
junction can mediate cell adhesion without the cytoplasmic tail of E-cadherin or its 
associated proteins, implying that Fyn activity is not necessary for adherens junction 
formation but may increase the efficiency of this process (Lampugnani et al, 1997).   
 
Counter to these findings, SFK activity is also required for the dissolution of adherens 
junctions.  KCs are constantly forming transient adhesions upon intercellular contact that 
must remain dynamic enough to allow movement of the KC through the layers of the 
epidermis (Lewis, Jensen and Wheelock, 1994, Tao et al, 1996).  However, if SFK 
activity is inhibited, KCs cannot free themselves from these dynamic adhesions, reducing 
cell motility (Owens et al, 2000).  Fyn phosphorylates β-catenin on tyrosine 142, 
disrupting the association between β-catenin and α-catenin and breaking apart the 
complex that connects the adherens junction to the actin cytoskeleton (Figure 4).  Other 
SFKs, especially Src and Yes, phosphorylate β-catenin more efficiently on Y654, 
triggering dissociation of β-catenin from E-cadherin (Roura et al, 1999).  Although Fyn 
exhibits greater preference for phosphorylation of β-catenin at Y142, it can also 
simultaneously phosphorylate β-catenin at Y654, resulting in complete dissociation of β-
catenin from the adherens junction and potential translocation of β-catenin to the nucleus 
where it can upregulate expression of TCF/LEF target genes (Piedra et al, 2003, Castano 
et al, 2007).  Overall, these findings indicate that within the epidermis, where KCs must 
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be able to adhere to each other but maintain these contacts in a fluid state, Fyn plays a 
dual role mediating adherens junction formation and dissolution.       
 
The biochemical consequences of Fyn-mediated p120catenin phosphorylation have not 
been completely resolved.  When Fyn phosphorylates p120catenin on Y112, the 
association of RhoA is blocked, resulting in increased RhoA activity, increased stress 
fiber formation and decreased conversion of the adherens junction from a strong to a 
weak state (Castano et al, 2007, Grosheva et al, 2001).  However, Fyn has also been 
shown to phosphorylate p120catenin and induce its dissociation from the adherens 
junction, resulting in activation of Cdc42 and Rac and inhibition of Rho activity (Figure 
4)(Grosheva et al, 2001, Anastasiadis et al, 2000).  Therefore Fyn has been shown to both 
increase and decrease Rho activity.  However, because Fyn activity primarily promotes 
the induction of a migratory phenotype, it appears more likely that Fyn is inhibiting Rho 
activity to reduce adhesion stability (Rengifo-Cam et al, 2004).  Finally, Fyn has been 
shown to phosphorylate E-cadherin to induce the association of Hakai, an E3 ligase that 
ubiquitinates E-cadherin and β-catenin to direct endocytosis of the adherens junction 
(Figure 4)(Fujita et al, 2002, Chen et al, 2009a).  Increased Src activity has also been 
shown to inhibit E-cadherin recycling back to the cell membrane, instead directing E-
cadherin to degradation in the lysosome (Wadhawan et al, 2011, Serrels et al, 2011).  
Although Fyn’s role in E-cadherin stability has not been completely determined, based on 
significant overlap in the function of SFK family members it is probable that Fyn also 
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reduces E-cadherin stability at the cell membrane (Alt-Holland et al, 2008).  Overall, 
Fyn-mediated phosphorylation of adherens junction proteins induces rearrangement of 
the actin cytoskeleton away from the adherens junction and toward focal contacts to 
initiate a more migratory phenotype (Rengifo-Cam et al, 2004).   
 
The experimental dermatologist is thus presented with two bodies of literature that 
characterize Fyn’s role in both the formation and dissolution of adherens junctions.  We 
propose that Fyn may initially increase the efficiency of adherens junction formation, 
recruiting key proteins to the cadherin to initiate binding with the actin cytoskeleton.  
After adherens junction assembly and with delayed kinetics, Fyn activity then results in 
the dissolution of the adherens junction through phosphorylation of β-catenin and 
p120catenin.  This apparently futile cycle may be responsible for the dynamic nature of 
the epidermal adherens junction.   
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Figure 4: Fyn at the Adherens Junction 
Assembly: During adherens junction assembly p120catenin associates with E-
cadherin, stabilizing the junction and creating a docking site for Fyn.  Fyn then 
tyrosine phosphorylates α-catenin and β-catenin to induce their association with 
the complex.   
Signaling: Once the adherens junction has assembled, Fyn activates signaling 
pathways resulting in KC differentiation and tyrosine phosphorylates β-catenin at 
Y142 and Y654* to disrupt the contact between the junction and the actin 
cytoskeleton. 
Dissolution: Fyn phosphorylates E-cadherin to induce Hakai association.   Hakai 
binds to and ubiquitinates (green arrows) E-cadherin and β-catenin to promote 
their internalization and degradation.  Fyn also phosphorylates p120catenin to 
inhibit Rho activity*, increasing the migratory capacity of the cells. 
* Dotted lines denote putative phosphorylation events. 
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1.5.4.2 Fyn’s Role at the Focal Adhesion 
 
Fyn activity shifts adhesion away from adherens junctions toward more migratory focal 
adhesions, where it plays an important role in maintaining the dynamic state of this 
complex (Rengifo-Cam et al, 2004).  Once integrins contact extracellular matrix proteins 
such as fibronectin they cluster, resulting in transient dimerization of the integrin-
associated protein FAK and auto- or transphosphorylation of FAK at Y397 (Figure 
5)(Schaller, Hildebrand and Parsons, 1999, Zeng et al, 2003).  Fyn activity has been 
implicated in this process; however FAK recruitment and phosphorylation at Y397 can 
occur in the absence of SFKs (Cary, Chang and Guan, 1996).  Similar to adherens 
junctions, Fyn activity may increase the efficiency of focal contact formation by aiding in 
FAK phosphorylation (Cary et al, 2002, Playford and Schaller, 2004).  Interaction 
between Fyn and FAK results in loss of Fyn’s inhibitory Y528 phosphorylation and 
autophosphorylation of the activating Y416 site.  Fyn then phosphorylates Y576/577 on 
FAK to maximize FAK’s enzymatic activity.  Fyn also phosphorylates FAK at Y925 to 
recruit Grb2, Y861 to recruit Paxillin or Talin, and Y407 (Figure 5)(Schaller, Hildebrand 
and Parsons, 1999, Yeo et al, 2011).  Although all of the SFKs are capable of 
phosphorylating FAK at these sites, Fyn induces focal contact formation more efficiently 
than Src or Yes due to its double palmitoylation (cysteine 3 and 6), which increases 
targeting to the plasma membrane and therefore the likelihood of association with FAK 
(Kostic and Sheetz, 2006).   
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At the focal adhesion Fyn recruits and phosphorylates several proteins that play a role in 
promoting cellular migration.  Fyn binds to and phosphorylates paxillin and p130Cas, 
both of which act to recruit Crk1, ultimately acting through the guanine exchange factor 
DOCK180 to activate Rac1 and inhibit RhoA, promoting cellular migration and 
facilitating adhesion turnover (Zeng et al, 2003, Sharma and Mayer, 2008, Peng and 
Guan, 2011).  Fyn also phosphorylates Shc to activate the 
Grb/mSOS/Ras/Raf/MEK/MAPK/ERK/MLCK pathway, promoting myosin and actin 
engagement to generate the force required for cell movement (Sharma and Mayer, 2008, 
Peng and Guan, 2011).  Ultimately, these signaling pathways result in the recruitment of 
dynamin to Grb2 and FAK at Y397.  Dynamin binds to microtubules and mediates the 
endocytosis of the integrin/FAK complex, disassembling the focal adhesion (Figure 
5)(Webb et al, 2004).  Thus, by aiding in focal adhesion formation Fyn paradoxically 
initiates signaling pathways that will ultimately result in junctional turnover. 
 
From the signaling mechanisms detailed above, it is clear that Fyn is necessary for the 
dynamic cycle of formation and dissolution at the focal contact.  This process is 
perturbed in the absence of Fyn as Fyn-/- FAK+/- KCs attach to the extracellular matrix 
but form atypically dense bundles of actin stress fibers, suggesting abnormally robust 
focal contact maturation (Schober et al, 2007).  When SFK phosphorylation sites on FAK 
are mutated, the cells can form protrusions but cannot disassemble focal contacts to allow 
the cell body to move forward (Brunton et al, 2005).  Further studies show that increased 
38 
 
 
 
SFK activity maintains focal complexes in an immature, dynamic state and induces their 
turnover (Guarino, 2010, Mitra and Schlaepfer, 2006).  Lamellipodia and filopodia, two 
migratory structures, are associated with smaller, more immature focal adhesions.  
FAK/SFK mediated inhibition of RhoA activity maintains these structures in their 
immature state and activates a signaling cascade that ultimately leads to focal adhesion 
endocytosis and dissolution (Playford and Schaller, 2004, Sharma and Mayer, 2008, Peng 
and Guan, 2011).  Because focal adhesions aid in migration, they must constantly be 
assembled at the leading edge of the cell and disassembled at the trailing edge.  
Upregulated Fyn activity induces KC migration by increasing the efficiency both of focal 
adhesion formation and dissolution.  As of this publication, Fyn subcellular localization 
and activity have not been studied in migrating cells, but such spatially and temporally 
resolved information may uncover a role for Fyn in the formation of focal adhesions at 
the leading edge of the cell and in focal adhesion dissolution at the trailing edge. 
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Figure 5: Fyn at the Focal Adhesion 
 
Assembly: Following integrin binding to extracellular matrix proteins, FAK 
molecules are brought in close proximity where they can auto- or trans-
phosphorylate Y397.  Phosphorylation of FAK Y397 induces loss of Fyn auto-
inhibition and Fyn-mediated phosphorylation of FAK at Y576, Y925, Y861 and 
Y407, maximizing FAK activity.  
Signaling: Fyn-mediated FAK phosphorylation results in the recruitment of Grb2 
and Paxillin.  Fyn then tyrosine phosphorylates p130cas and Paxillin to induce the 
association of Crk1.  Fyn also phosphorylates Shc to induce Grb2-mediated 
activation of the Ras/MAPK/MLCK pathway.  
Dissolution: Crk1 recruits DOCK180 to increase Rac activity and inhibit Rho 
activity.  Together these signaling mechanisms result in focal adhesion turnover 
and increased cell migration. 
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1.5.4.3 Fyn’s Role at the Desmosome and Hemidesmosome 
 
Less is known about the role of Fyn at the desmosome and hemidesmosome.  However, it 
appears that Fyn plays a similar dichotomous role at these sites as it does in adherens 
junctions and focal adhesions by increasing the efficiency of adhesion initiation, then 
ultimately aiding in hemidesmosomal and desmosomal dissolution (Mariotti et al, 2001, 
Spinardi et al, 2004, Gagnoux-Palacios et al, 2003).  Blocking SFK activity inhibits 
hemidesmosome formation, while inhibition of Fyn also increases the stability of the 
hemidesmosome once they are formed (Spinardi et al, 2004).  Fyn activation has been 
shown to trigger desmosome dissolution through the 
Shc/Grb2/mSOS/Ras/RAF/MEK/ERK pathway and Shc/Grb1/mSOS/Ras/PI3K/Rac/JNK 
pathway (Mariotti et al, 2001, Gagnoux-Palacios et al, 2003)   
 
1.6 The Epithelial-to-Mesenchymal Transition (EMT) 
 
Epithelial tissues are made up of polarized, tightly adherent cells that form continuous 
sheets to protect underlying structures, regulate the exchange of chemicals and other 
substances, secrete hormones and body products and provide sensation.  For various 
biological reasons, these epithelial cells can undergo a transition to a mesenchymal cell 
phenotype, increasing their migratory capacity, invasiveness, resistance to apoptosis and 
secretion of extracellular matrix proteins (Kalluri and Weinberg, 2009a).  This change in 
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cell phenotype is called the epithelial-to-mesenchymal transition, or EMT, and it occurs 
in three different biological settings.  The first, termed Type I EMT, occurs during 
embryo formation and organ development (Zeisberg and Neilson, 2009).  Type II EMT is 
associated with wound healing, tissue regeneration and organ fibrosis (Kalluri and 
Weinberg, 2009a).  The most pertinent to this project, Type III EMT occurs in 
transformed, neoplastic cells, increasing their malignant potential and allowing these cells 
to detach from the basement membrane and invade the circulatory system to form distant 
metastases (Thiery, 2002).  This process is more of a spectrum than an on/off switch, 
with cells undergoing different degrees of transition towards the mesenchymal 
phenotype.  Ultimately, changes in cell signaling and gene expression result in 
downregulation of cell-cell and cell-matrix junctions, a switch from apical-basal polarity 
to front-rear polarity and a reorganization of the cytoskeleton to change the cell shape and 
allow the formation of cell protrusions (Lamouille, Xu and Derynck, 2014). 
 
1.6.1 EMT in cSCC 
 
All three types of EMT are seen in the skin.  During embryogenesis, Type I EMT is 
necessary for the formation of the epidermis and dermis.  Type II EMT is necessary 
during wound healing, when keratinocytes reduce their adhesions and migrate into the 
wound margin to aid in closure (Nakamura and Tokura, 2011).  Type III EMT is also 
seen in cSCC, although it is considered to be a rare event as only 5% of cSCCs 
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metastasize (Toll et al, 2013).  Those cSCCs that do undergo EMT are most often part of 
a particularly malignant subgroup defined as spindle cell carcinomas.  Spindle cell 
carcinomas are histologically defined by the presence of elongated keratinocytes that 
invade the dermis as individual cells (Nakamura and Tokura, 2011, Klein-Szanto, 1989, 
Shimokawa et al, 2013).  Despite the low occurrence of EMT in cSCC, loss of E-
cadherin, an important marker of EMT, is associated with advanced cSCC progression, 
metastasis and poor clinical prognosis (Alt-Holland et al, 2008). 
 
1.6.2 Signaling in EMT 
 
Paradoxically, many commonly accepted oncogenes such as Ras induce senescence 
following their upregulation or activation in normal cells.  Activation of the EMT 
process, however, increases cellular resistance to senescence, ultimately promoting the 
survival of the tumor and increasing the ability of the transformed cell to travel to other 
sites (Smit and Peeper, 2008, Ansieau et al, 2008, Weinberg, 2008).  Extracellular growth 
factors such as HGF, EGF, PDGF and TGF-β, as well as WNT and Notch signaling, 
activate transcription factors such as Snail, Slug, ZEB1, Twist, Goosecoid and FOXC2 to 
drive the changes in gene expression that result in EMT (Kalluri and Weinberg, 2009b, 
Yilmaz and Christofori, 2009).  Ultimately these alterations activate signaling pathways 
involving ERK, MAPK, PI3K, Akt, Smads, Rho, β-catenin, LEF, Ras, c-FOS, β4 
integrins, α5β1 integrin and αVβ6 integrin (Tse and Kalluri, 2007).  Reduction of 
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adherens junction and focal adhesion stability result in an increased migratory capacity, 
facilitating the transition to a mesenchymal phenotype (Kalluri and Weinberg, 2009b).  
EMT also induces the expression of NCAM, which interacts with Fyn to increase focal 
adhesion assembly and cell migration (Lehembre et al, 2008). 
 
1.6.3 Transcription Factors Mediating EMT 
 
EMT requires activation of genes that characterize a mesenchymal phenotype and 
repression of genes that characterize an epithelial phenotype.  This global change in gene 
expression is regulated primarily through three families of transcription factors: Snail, 
Twist and Zeb.  The Snail family of transcription factors includes Snail (SNAI1) and 
Slug (SNAI2).  Snail acts to bind the E-box sequence of the CDH1 promoter region, 
where it recruits the Polycomb repressive complex 2 to acetylate histone H3K9 and 
methylate histones H3K9, H3K27 and H3K4.  Methylation of H3K9 and H3K27 repress 
CDH1 (E-cadherin) transcription, while methylation of H3K4 and acetylation of H3K9 
activate CDH1 transcription.  Through this combination of repressive and activating 
modifications Snail creates a state of repression, while still allowing rapid activation of 
transcription and reversal of EMT.  The Snail family of transcription factors is activated 
by the TGF-β-SMAD2, WNT-β-catenin, Notch, PI3K-Akt, NF-κB, EGF and FGF 
signaling pathways.  Together, Snail and Slug downregulate the expression of E-
cadherin, Claudins, Occludin, Crumbs3, Pals1, Cytokeratins, Desmoplakin and 
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Plakophilin while upregulating expression of Fibronectin, N-cadherin, Collagen, 
MMP15, MMP2, MMP9, Twist, Id1, Id2, Zeb1 and Zeb2 (Lamouille, Xu and Derynck, 
2014).  Activation of the ZEB family of transcription factors by Snail, TGFβ-SMAD3, 
WNT-β-catenin or Ras-MAPK or through repression of the microRNA-200 family 
results in downregulation of E-cadherin, Zo1, Crumbs3 and Plakophilin expression and 
upregulation of N-cadherin and matrix metalloproteases (Lamouille, Xu and Derynck, 
2014, Enkhbaatar et al, 2013).  Twist acts through Snail-independent mechanisms to 
recruit SET8 to target promoters and methylate histone H4K20, repressing E-cadherin 
and upregulating N-cadherin expression (Lamouille, Xu and Derynck, 2014).  Twist 
family members are activated by β-catenin and the MAPK signaling pathway to 
downregulate E-cadherin, Claudins, Occludins, Desmoplakin and Plakoglobin expression 
and upregulate Fibronectin, N-cadherin and α5 integrin (Lamouille, Xu and Derynck, 
2014, Scanlon et al, 2013).   
 
SFKs also regulate expression of Slug, Snail and Twist.  Although little is known about 
the interaction of Fyn and these transcription factors, increased SFK activity directly 
targets Slug and Twist to induce EMT.  In both breast and lung cancer cell lines, 
inhibition of SFK activity reversed characteristics of the EMT phenotype and 
downregulated expression of Slug, suggesting Src activity was driving Slug expression 
levels (Liu and Feng, 2010, Joannes et al, 2014).  SFK activity has also been shown to 
45 
 
 
 
increase the transcription and activity of Twist in leukemia and breast cancer cells 
(Bourguignon et al, 2010, Kim et al, 2013, Cheng et al, 2008).   
 
1.6.4 Changes in Adhesion and Cytoskeletal Structure 
 
One of the hallmarks of EMT is the downregulation of stable cell-cell junctions, 
including tight junctions, desmosomes and adherens junctions.  Adherens junction 
stability is decreased both by reducing levels of E-cadherin at the cell membrane and 
inhibiting E-cadherin gene transcription.  The stability of E-cadherin at the cell 
membrane is decreased through cleavage of its cytoplasmic domain, increasing levels of 
free cytoplasmic β-catenin and p120catenin to alter the cell’s transcriptional program 
(Lamouille, Xu and Derynck, 2014).  Levels of E-cadherin at the cell membrane are also 
decreased through endocytosis and Src-mediated ubiquitination and degradation (Yilmaz 
and Christofori, 2009, Fujita et al, 2002).  Downregulation of E-cadherin expression is 
countered by increased expression of the mesenchymal neural cadherin N-cadherin, often 
called the cadherin switch, resulting in increased affinity for mesenchymal cells and 
decreased strength of cell-cell adhesions (Yilmaz and Christofori, 2009, Lamouille, Xu 
and Derynck, 2014).   
 
Establishing a front-rear polarity allows differential regulation of the actin cytoskeleton at 
the front and back of the cell.  Following the initial activation of the EMT program, 
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RhoA and its downstream effectors ROCK and DIA1 are activated to increase the 
formation of actin stress fibers (Lamouille, Xu and Derynck, 2014).  RhoA continues to 
be active at the rear of the cell, where it promotes the disassembly of cell-matrix 
adhesions and initiates cell retraction (Nelson, 2009).  At the front edges of the cell the 
downregulation of adherens junctions increases the amount of cytoplasmic p120catenin, 
inhibiting RhoA activity and increasing the instability of cell junctions in this region.  
Activation of Rac1 and CDC42 at the front of the cell increases the formation of 
lamellipodia and filopodia, increasing the motility of the cell (Whale et al, 2011, 
Anastasiadis and Reynolds, 2001).  Together these processes result in cell movement and 
migration.   
 
SFKs inhibit RhoA and activate Rac1 to alter the structure of the actin cytoskeleton (Yagi 
et al, 2007).  During adhesion initiation, Src complexes with FAK to recruit Rac-
activating GEFs such as Tiam1, DOCK180, Vav and PIX at immature focal adhesions, 
activating Rac to induce lamellipodia formation (Huveneers and Danen, 2009).  Src also 
activates p190RhoGAP, increasing levels of GDP-bound Rho and inhibiting Rho activity 
(Brandt et al, 2002).  In cancer cell metastases, Src suppresses RhoA to relax the actin 
cytoskeleton and allow podosome formation (Clark et al, 2007).  During oligodendrocyte 
differentiation, Fyn phosphorylates p190RhoGAP to decrease Rho activity.  Fyn also 
activates Rac and Cdc42, and together with Rho inhibition these signaling changes 
induce process extension and differentiation of the oligodendrocytes (Wolf et al, 2001, 
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Liang, Draghi and Resh, 2004).  Fyn-mediated phosphorylation of p250GAP in neurons 
has also been implicated in Rho inhibition and oligodendrocyte differentiation (Taniguchi 
et al, 2003).   
 
1.6.5 SFKs and EMT 
 
SFKs are involved in cell processes that regulate proliferation, survival, regulation of the 
cytoskeleton and cell shape, maintenance of cell-cell and cell-matrix adhesions, motility 
and migration (Guarino, Rubino and Ballabio, 2007).  Therefore, when proteins from this 
family are dysregulated it alters many of the characteristics important in EMT.  In head 
and neck SCCs there is a correlation between Src over-expression and E-cadherin 
downregulation, vimentin upregulation and invasiveness (Mandal et al, 2008).  Src 
activation plays a key role in the induction of EMT by upregulating the production of 
matrix metalloproteases, phosphorylating caspase-8 to induce its pro-migratory function 
and disrupting cell-cell junctions (Rivat et al, 2003, Frisch, 2008, Behrens et al, 1993).  
More specifically, Src phosphorylates β-catenin, disrupting the interaction between E-
cadherin and β-catenin and reducing the stability of the adherens junction (Behrens et al, 
1993).  β-catenin can then travel to the nucleus where it upregulates pro-EMT genes such 
as Snail, Vimentin and matrix metalloproteases (Guarino, Rubino and Ballabio, 2007).  
Sequestration of β-catenin in adherens junctions suppresses tumor formation through 
contact inhibition, and the liberation of β-catenin by SFKs contributes to the oncogenic 
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activity of this family of proteins.  Src also phosphorylates E-cadherin to target the 
adherens junction protein for endocytosis and degradation (Avizienyte and Frame, 2005, 
Palacios et al, 2005).  Upregulation of Fyn activity has been associated with the induction 
of EMT in oral SCC through downregulation of Cytokeratin and E-cadherin and 
upregulation of N-cadherin and vimentin (Lewin et al, 2010).  Increased Fyn activity has 
also been associated with the induction of EMT in colorectal cancer (Wang et al, 2012).  
Thus it is clear that SFKs, including Fyn, play an important role in the transformation 
from an epithelial to a mesenchymal cell phenotype. 
 
1.7 Dasatinib 
 
Dasatinib (BMS-354825, Sprycel®; Bristol Myers Squibb) is a small molecule tyrosine 
kinase inhibitor that blocks SFK, BCR-ABL, EphA2, c-FMS, PDGFR and c-Kit activity 
by binding to the ATP-binding site of these tyrosine kinases and competitively inhibiting 
ATP binding (Aguilera and Tsimberidou, 2009, Gnoni et al, 2011).  Despite the fact that 
Dasatinib has a broad specificity, the in vitro IC50 necessary to inhibit SFK activity is 0.5 
nM, lower than any of its other targets (Aguilera and Tsimberidou, 2009, Lombardo et al, 
2004).   The most clinically studied SFK inhibitor, Dasatinib is already used in clinics to 
treat Imatinib-resistant chronic myelogenous leukemia (CML) and Philadelphia 
chromosome positive acute lymphoblastic leukemia (ALL), and is being evaluated in 
clinical trials to treat a variety of solid tumors (Araujo and Logothetis, 2010, Gnoni et al, 
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2011).   
 
Dasatinib is orally administered drug that reaches its maximum plasma concentration 
within 3-5 hours and has a half-life of 3-5 hours.  Highly protein bound, Dasatinib 
reaches extensive distribution in the extravascular space but has poor brain penetration.  
The majority of Dasatinib is metabolized in the liver by CYP3A4 to produce the 
pharmacologically active metabolites M4, M5, M6, M20 and M24.  Following its 
metabolism, 96% of Dasatinib is excreted in the feces and 4% is excreted in the urine 
(van Erp, Gelderblom and Guchelaar, 2009).  When administered every twelve hours for 
5 consecutive days followed by 2 non-treatment days for the treatment of solid tumors the 
maximum tolerated dose was 120 mg.  When administered continuously twice daily for 
the treatment of solid tumors the maximum tolerated dose was 70 mg.  Dose limiting 
toxicities included nausea, fatigue and anorexia (Demetri et al, 2009).   
 
1.7.1 Role for Dasatinib in the Treatment of Cancer 
 
Dasatinib was originally developed as an inhibitor of SFKs, although its initial clinical 
use was as an inhibitor of BCR-ABL in CML and ALL (Montero et al, 2011).  SFKs are 
upregulated in most solid tumors; therefore targeting this dysregulation using Dasatinib is 
a promising clinical therapy (Varkaris et al, 2014, Yeatman, 2004, Frame, 2004, Mandal 
et al, 2008).  Studies in prostate cancer have shown that Dasatinib-mediated SFK 
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inhibition directly blocks properties associated with cellular metastasis.  Furthermore, 
prostate tumors from mice treated with Dasatinib were smaller and resulted in a reduced 
incidence of lymph node metastases (Park et al, 2008).  Dasatinib treatment in triple 
negative breast cancer cell lines (MDA-MB-231 cells) inhibited cell cycle progression 
and stimulated apoptosis while also inhibiting cellular invasion and migration (Nautiyal 
et al, 2009).  Studies of non-small cell lung cancer, colorectal cancer, pancreatic cancer, 
head and neck squamous cell carcinoma and melanoma have recapitulated these results, 
indicating Dasatinib treatment inhibits cell migration and invasion, with variable ability 
to inhibit cell proliferation and survival (Araujo and Logothetis, 2010, Montero et al, 
2011).  Additionally, Dasatinib exposure results in significantly reduced osteoclast 
activity through inhibition of FMS, the tyrosine kinase receptor of the macrophage 
colony-stimulating factor (Brownlow et al, 2009).  Therefore, Dasatinib both reduces the 
ability of cells to migrate from the primary tumor and the process of osteolysis that 
creates an attractive environment for bone metastasis (Araujo and Logothetis, 2010, 
Montero et al, 2011).    
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1.8 Hypothesis and Aims 
 
More than 700,000 patients are diagnosed with cSCC every year, and this number is only 
growing as UV exposure increases due to changing lifestyles and a thinning ozone layer.  
Despite the personal and economic impact of cSCC, there are no targeted therapies to 
treat this type of tumor.  The introduction of H-Ras, a common oncogene in cSCC, is 
sufficient to selectively upregulate Fyn expression in HaCaT cells, a human keratinocyte 
cell line.  SFKs activity is upregulated in most tumor types (including cSCC), and this 
increase is associated with tumor progression and decreased survival.  The introduction 
of active Fyn to the epidermis of a mouse is sufficient to induce the formation of AKs 
and cSCCs.  For these reasons, targeting Fyn activity may be an effective clinical therapy 
in the treatment of cSCC.   
 
1.8.1 Hypothesis 
 
Fyn expression and activity in keratinocytes is upregulated following the introduction of 
active Ras, a common oncogene in cSCC.  Within the context of cellular transformation 
and oncogenesis, Fyn activity is associated with the transition from an epithelial to 
mesenchymal phenotype, as well as an increase in the migratory capacity of tumorigenic 
cells.  Targeting Fyn in Ras-transformed keratinocytes may serve as a potential therapy in 
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the treatment of cSCC, as well as increase our understanding of how increased Fyn 
activity drives the malignant phenotype of keratinocytes. 
 
1.8.2 Aims 
 
1.8.2.1 Aim 1 
 
Although Fyn is overexpressed in many tumors, the signaling mechanism controlling the 
transcriptional regulation of Fyn expression has only been identified in leukemic white 
blood cells.  Therefore, we will determine the mechanism regulating Fyn over-expression 
in HaCaT cells stably expressing constitutively active H-Ras. 
 
1.8.2.2 Aim 2 
 
Increased Fyn activity has been linked to many of the characteristics associated with 
tumors that have an increased migratory and metastatic capacity.  Progression to a pro-
migratory phenotype is associated with poor clinical outcomes in cSCC.  Therefore, we 
will determine whether targeting Fyn can reverse these pro-migratory characteristics and 
elucidate the mechanism by which Fyn inhibition decreases cell mobility.   
 
 
53 
 
 
 
1.8.2.3 Aim 3 
 
Increased Fyn activity is associated with increased tumor formation in the epidermis, and 
inhibition of SFKs decreases papilloma formation following chemical carcinogenesis.  
Therefore, we will determine whether Dasatinib treatment following UV exposure, a 
common carcinogen in cSCC, reduces tumor formation in vivo. 
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CHAPTER II 
MATERIALS AND METHODS 
 
2.1 Cell Culture and Reagents 
 
HaCaT, HaCaT-Ras and HaCaT-Fyn cell lines were grown in DMEM with 10% FBS, 
1% penicillin/streptomycin or Media 154 (0.07 mM Ca2+) for low Ca2+ experiments 
(Invitrogen, Grand Island, NY).  MDA-MB231 cells were grown in IMEM with 5% FBS, 
1% penicillin/streptomycin, 1% L-Glutamine and 1% non-essential amino acids 
(Invitrogen, Grand Island, NY).  Active H-Ras(G12V) was expressed from the LZRS 
retroviral vector, while active Fyn (I338T) was expressed from the pMV7 retroviral 
vector (Yadav and Denning, 2011).  Dasatinib (LC Laboratories, Woburn, MA), 
Cytochalasin D (Santa Cruz Biotechnology Inc., Dallas, TX) and Y27632 (Millipore Inc., 
Billerica, MA) were purchased from the companies indicated.   
 
2.2 Reverse Transcriptase qPCR 
 
Total RNA was isolated using Trizol (Invitrogen, Grand Island, NY).  Complementary 
DNA was synthesized using the Superscript First Strand Synthesis system (Invitrogen, 
Grand Island, NY).  Quantitative RT-PCR was performed using a GeneAmp 5700 
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sequence detection system (Applied Biosystems, Carlsbad, CA) with Platinum SYBR 
Green PCR reagents (Invitrogen, Grand Island, NY).  GAPDH or β-actin was used to 
normalize expression levels and relative mRNA expression was calculated using the 
ΔΔCt method.  More specifically, ΔΔCt was calculated by subtracting the average Ct 
values of the gene of interest from the average Ct values of the housekeeping control 
gene to generate the ΔCt value.  The control sample was used to compare all other 
samples to and the ΔCt of this control sample was subtracted from the ΔCt value of all 
other samples to generate ΔΔCt values.  Data is represented as mean ΔΔCt ± standard 
deviation.  Positive standard deviations were calculated by subtracting 2 raised to – ΔΔCt 
from 2 raised to –(ΔΔCt – the square root of the standard deviation of the Ct values of the 
gene of interest squared plus the standard deviation of the Ct values of the control 
housekeeping gene squared).  Negative standard deviations were calculated by 
subtracting 2 raised to –(ΔΔCt plus the square root of the standard deviation of the Ct 
values of the gene of interest squared plus the standard deviation of the Ct values of the 
control housekeeping gene squared) from 2 raised to –ΔΔCt. 
The RT-qPCR primers used are as follows: 
Src Forward: 5’-GTCAAGCTGGGCCAGGGCTG-3’ 
Src Reverse: 5’-TGACCTGGGCCTCCTGCAGG-3’ 
Fyn Forward: 5’-GGCAGCCCTGTACGGGAGGT-3’ 
Fyn Reverse: 5’-GCTCCACCTGCTCCAGCACC-3’ 
Fyn(B) Forward: 5’-GCCGCTAGTAGTTCCCTGT-3’ 
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Fyn(T) Forward: 5’-AGATGCTTGGGAAGTTGCAC-3’ 
Fyn(B)/(T) Reverse: CTTCATGATCTGCGCTTCCT-3’ 
Yes Forward: 5’-GACTCATGAGAGCGCGGCCG-3’ 
Yes Reverse: 5’-TGGCTCACACTTGTACTGACAGGCT-3’ 
FGR Forward: 5’-ATCATGCCGCAGCCCCACTG-3’ 
FGR Reverse: 5’-CGTGGCCACCGGCTCCAATT-3’ 
Lyn Forward: 5’-GCGCTGGGCAGTTTGGGGAA-3’ 
Lyn Reverse: 5’-GGGCTCCTCCCTGGTGACCA-3’ 
Hck Forward: 5’-GCCACCCGGAAGGAGGGCTA-3’ 
Hck Reverse: 5’-AGCCAGCAGGTTGGCGCTCTG-3’ 
Lck Forward: 5’-CACGGCCGCATCCCTTACCC-3’ 
Lck Reverse: 5’-CTGGGCGCTCCTTCCAGCAC-3’ 
Blk Forward: 5’-GGCGGCCAACATCCTGGTGT-3’ 
Blk Reverse: 5’-ATGGCTTCCGGGGCTGTCCA-3’ 
GATA1 Forward: 5’- CTCCGCAACCACCAGCCCAG-3’ 
GATA1 Reverse: 5’-GCATCCAAGCCCTCAGGCCC-3’ 
GATA2 Forward: 5’-GACCGGCCTCCAGCTTCACC-3’ 
GATA2 Reverse: 5’-AGGCCACAGGCATTGCACAGG-3’ 
GATA3 Forward: 5’-CAAGGCCCGCTCCAGCACAG-3’ 
GATA3 Reverse: 5’-CCGCAGGCGTTGCACAGGTA-3’ 
LEF1 Forward: 5’-TGCAGCCATCCCATGCGGTC-3’ 
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LEF1 Reverse: 5’-ACACCACCCGGAGACAAGGGA-3’ 
TCF4 Forward 5’-GAGCCATGGGTGGTCTGGGC-3’ 
TCF4 Reverse 5’-CTGCCTCTCAGGGGCCACGC-3’ 
β-catenin Forward 5’-TTGTCCCGCAAATCATGCAC-3’ 
β-catenin Reverse 5’-GCTAGGATGTGAAGGGCTCC-3’ 
Snail (Snai1) Forward 5’-CAAGATGCACATCCGAAGCC-3’ 
Snail (Snai1) Reverse 5’-CATCTGAGTGGGTCTGGAGG-3’ 
Slug (Snai2) Forward 5’-CATCTTTGGGGCGAGTGAGT-3’ 
Slug (Snai2) Reverse 5’-ATGGCATGGGGGTCTGAAAG-3’ 
Twist1 Forward 5’-TCTACCAGGTCCTCCAGAGC-3’ 
Twist1 Reverse 5’-CTCCATCCTCCAGACCGAGA-3’ 
GAPDH Forward: 5’-CGACCGTCAAGGCTGAGAAC-3’ 
GAPDH Reverse: 5’-GCCTTCTCCATGGTGGTGAA-3’ 
Fyn promoter Forward: 5’-TGCCACAGTAACGCTCAACCCACT-3’ 
Fyn promoter Reverse: 5’-CCCGGCTGCCCTATCAAAGA-3’ 
 
2.3 Luciferase Assays 
 
The pFynPromoterCheck reporter plasmid was a gift from Dr. Joya Chandra (MD 
Anderson, Houston, TX) (Gao et al, 2009).  A 2 kb segment of the human FYN promoter 
was excised from the pFynPromoterCheck plasmid using BglII and HindIII and then 
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ligated into a pGL3-Basic plasmid (Promega, Madison, WI) to generate pFyn2000.  
Plasmids containing 1 kb, 0.5 kb, 0.1 kb and 0.05 kb of the FYN promoter were generated 
using the same method.  A pFyn2000 plasmid containing a mutation at the site of interest 
was generated using the QuikChange Lighting Site-Directed Mutagenesis kit (cat# 
210518, Agilent Technologies, Santa Clara, CA) (Forward primer 
5’CCAAGGGCTCTTTCTTAGGGCAGCCGGG-3’ Reverse primer 5’-
CCCGGCTGCCCTAAGAAAGAGCCCCTTGGG-3’).  200,000 cells/well in a 12 well 
plate were transfected with 1.4 μg DNA/well (1.2 μg firefly and 0.2 μg renilla luciferase 
plasmids) using 4 μL TransIT-2020/well (Mirus Bio LLC, Madison, WI) in Opti-MEM 
(Invitrogen, Grand Island, NY) with a final volume of 200 μL/well.  Reporter plasmid 
activity was assessed 48 hours post-transfection using the Dual Luciferase Reporter 
Assay (Promega, Madison, WI) with transfection efficiency normalized using the pRL-
TK renilla luciferase plasmids (Promega, Madison, WI).  Luciferase was measured using 
the Femtomaster FB15 (Zylux Corporation, Oak Ridge, TN).  Data is represented as 
mean firefly luciferase/renilla luciferase ± standard deviation. 
 
2.4 Transcription Factor Prediction Analysis 
 
Predicted transcription factor binding was performed by entering the sequence of the 
promoter region of interest into the following websites: 
TF Search: http://www.cbrc.jp/research/db/TFSEARCH.html 
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ALGGEN/PROMO: http://alggen.lsi.upc.es/cgi-
 bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3 
TFBind: http://tfbind.hgc.jp/ 
TFSiteScan: http://www.ifti.org/cgi-bin/ifti/Tfsitescan.pl 
 
2.5 Chromatin Immuno-Precipitation Assay 
 
The Chromatin Immunoprecipitation (ChIP) assay was performed using the EZ-ChIP kit 
(cat#17-371 Millipore Inc., Billerica, MA).  Briefly, the cells were incubated in 1% 
formaldehyde for 10 minutes.  The reaction was neutralized by incubation in 1% glycine 
for 5 minutes.  The cells were then lysed in SDS lysis buffer and sonicated at 50% power 
for 10 seconds 8-10x on ice.  Cross-linked protein and DNA were incubated overnight at 
4°C with rotation and with 2 μg of one of the antibodies listed below.  Protein G agarose 
beads were added and the mixture was incubated for one hour at 4°C with rotation.  The 
isolates were washed with low-salt immune complex buffer, high-salt immune complex 
buffer, LiCl immune complex buffer and TE buffer.  The cross-linked protein and DNA 
were eluted from the beads by incubating the isolates with elution buffer at room 
temperature for 15 minutes. Crosslinking was reversed by incubating the isolate with 5M 
NaCl at 65°C for 5 hours.  The DNA was isolated using spin filters provided.  The Fyn 
promoter sequence was detected by performing qPCR as described above.   
Antibodies used:  
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Gata2 SC-9008 Santa Cruz Biotechnology Inc., Dallas, TX 
Gata3 SC-22206 Santa Cruz Biotechnology Inc., Dallas, TX 
Lef-1 SC-8591 Santa Cruz Biotechnology Inc., Dallas, TX 
β-catenin SC-7199 Santa Cruz Biotechnology Inc., Dallas, TX 
 
2.6 Electrophoretic Mobility Shift Assay (EMSA) 
 
EMSA was performed by first annealing the oligonucleotides corresponding to the region 
of interest.  Oligonucleotides were purchased from IDT with the IRdye700 added to the 
5’ end and were HPLC purified.  Equal molar quantities of the forward and reverse 
oligonucleotide were heated in a 100°C heating block for 3 minutes in the dark.  The 
block was then turned off and the oligonucleotides were allowed to slowly come to room 
temperature.  Following the annealing of the oligonucleotides, a 4% native agarose gel 
was made.  The oligonucleotides were combined with 10x binding buffer (100 mM Tris, 
500 mM KCl, 10 mM DTT, pH 7.5), 1 ug/uL poly(dI-dC), 25 mM DTT/2.5% Tween20, 
7.5 ug nuclear extract and enough water to total 20 uL.  30% glycerol was added and the 
mixture was allowed to incubate in the dark for 30 minutes.  Alternatively, if a supershift 
was desired everything but the oligonucleotide was mixed and allowed to incubate for 10 
minutes.  Then the oligonucleotide was added and the mixture was allowed to incubate 
for 30 minutes.  The sample was then loaded into the native gel with a mixture of 
glycerol and bromphenol blue in an adjacent lane and was run at 40V until the dye 
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reached 2/3 of the way down the gel.  Agarose gels were visualized using the LI-COR 
Infrared Imaging System (Li-Cor Biosciences, Lincoln, NE).   
Antibodies used: Lef-1 SC-8591 Santa Cruz Biotechnology Inc., Dallas, TX 
Oligonucleotide sequences: 
EMSA Fyn pro forward: 5’-/5IRD700/GGCTCTTTGATAGGGCAGCC-3’ 
EMSA Fyn pro reverse: 5’-5IRD700/GGCTGCCCTATCAAAGAGCC-3’ 
 
2.7 Immunoblotting 
 
Western blotting was performed as described previously (D'Costa et al, 2006).  Cell 
lysates were collected by scraping cultured cells in RIPA buffer (50mM Tris, ph7.5, 150 
mM NaCl, 1% Triton X-100, 0.1% SDS, 1% Sodium Deoxycholate) and were cleared by 
centrifuging at 14,000 rpm at 4°C for 5 minutes.  Protein concentrations were determined 
using Bradford reagents (Bio-Rad, Hercules, CA).  Antibodies were obtained from the 
companies indicated: Fyn-59 (SC-73388, Santa Cruz Biotechnology Inc., Dallas, TX), E-
cadherin (INV135700, Invitrogen, Grand Island, NY), pan-cytokeratin AE1/AE3 (SIG-
3464, Covance, Princeton, NJ), vimentin (AMF-17b, Developmental Studies Hybridoma 
Bank, Iowa City, IA) and β-actin (MP691002, MP Biomedicals, Santa Ana, CA).  
Secondary antibodies used were goat anti-rabbit IgG-Alexa Fluor 680 or 800 and goat 
anti-mouse IgG-AlexaFluor 680 or 800 (Invitrogen, Grand Island, NY).  Western blots 
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were visualized using the LI-COR Infrared Imaging System (Li-Cor Biosciences, 
Lincoln, NE).   
 
F-actin and G-actin fractionation was performed as described by Rasmussen et al. 
(Rasmussen et al, 2010).   Cells were lysed in cold actin stabilization buffer (0.1 M 
PIPES, 10% glycerol, 20x DMSO, 1 μM MgSO4, 2 μM EGTA, 1% TX-100, 10x ATP 
and 25x complete protease inhibitor) on ice for 10 minutes.  G-actin was isolated by 
centrifuging the sample at 12,500 rpm in the Beckman TL-100 Ultracentrifuge (Beckman 
Coulter, Inc., Brea, CA) for 75 minutes at 4°C.  The pellet was then resolubilized in actin 
depolymerization buffer (0.1M PIPES, 1 μM MgSO4, 10 μM CaCl2 and 5 μM 
Cytochalasin D) for 10 minutes at room temperature to obtain F-actin.  Samples were run 
on a Western blot as described above.  Bands were quantitated using Image-J Software. 
 
2.8 SFK Activation Assay 
 
SFK activation was determined using the Milliplex Map 8-Plex Human Src Family 
Kinase Phosphoprotein kit (Millipore Inc., Billerica, MA) and the Flexmap 3D Luminex 
system (Luminex Corporation, Austin, TX) as directed by the manufacturer.   
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2.9 AlamarBlue Assay 
 
Cell viability was measured by incubating the cells with alamarBlue (Invitrogen, Grand 
Island, NY).  Following treatment, alamarBlue was introduced to the cell culture at a 1:20 
dilution in growth media.  The cells were then allowed to incubate at 37°C for 2 hours.  
Changes in fluorescence were measured using a POLARstar Omega plate reader (BMG 
Labtech, Ortenberg, Germany) by detecting fluorescence from the bottom of the plate.  
Excitation was set at 530 nm and emission was set at 590 nm.    
 
2.10 DNA Quantitation Assay 
 
Cellular proliferation was measured using the DNA Quantitation Kit from Bio-Rad (cat # 
1702480, Bio-Rad, Hercules, CA).  Following treatment cells were exposed to PBS- with 
0.1% EDTA for 10 minutes.  The cell lysate was then mixed with Hoechst dye in a 96 
well plate and a standard curve with control DNA was set up adjacent to the samples.  
DNA quantitation was performed by detecting fluorescence emission using a POLARstar 
Omega plate reader (BMG Labtech, Ortenberg, Germany) with the excitation filter set at 
360 nm and the emission filter set to 460.  
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2.11 Thymidine Incorporation Assay 
 
Cellular proliferation was measured by incubating the cells in media containing 5 μCi 
radioactive thymidine overnight.  The cells were then trypsinized, transferred to 96 well 
UniFilters (PerkinElmer, Waltham, MA) and read on a scintillation reader.   
 
2.12 DNA-PI Staining 
 
Cell cycle analysis was performed by trypsinizing the cells and placing them in flow 
cytometry tubes.  The cells were washed with cold FACS buffer (PBS+ with 5% FBS and 
0.2% sodium azide), then incubated 30 minutes on ice with 85% cold EtOH.  After 
washing the cells with another aliquot of FACS buffer, the cells were treated with 10 
μg/mL RNaseA for 15 minutes at 37°C and 5 minutes at room temperature.  An equal 
volume of propidium iodide (100 μg/mL) was then added and the cells were incubated in 
the dark at 4°C for 1 hour.  Propidium iodide staining was measured using either a 
Coulter Epics XL-MCL flow cytometer (Beckman Coulter, Brea, CA) or a BD 
FACSCANTO II flow cytometer (BD Biosciences, San Jose, CA).   
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2.13 Annexin-PI Staining 
 
Apoptosis was measured using the Dead Cell Apoptosis Kit (cat # V13245, Invitrogen, 
Grand Island, NY) by trypsinizing the cells and placing them in flow cytometry tubes.  
The cells were washed with cold PBS- and were resuspended in cold binding buffer.  
Annexin and propidium iodide were added to the cell suspension and the mixture was 
allowed to incubate in the dark for 15 minutes.  Cold binding buffer was added and 
apoptosis was measured using a Coulter Epics XL-MCL flow cytometer within one hour 
(Beckman Coulter, Brea, CA).   
 
2.14 Acridine Orange Staining 
 
Autophagy was measured using Acridine Orange (cat # A1301, Invitrogen, Grand Island, 
NY).  Cells were incubated in a 1μg/mL solution of Acridine Orange in DMEM media 
for 20 minutes at 37°C.  The cells were trypsinized and resuspended in PBS+.  
Autophagy was measured using a Coulter Epics XL-MCL flow cytometer (Beckman 
Coulter, Brea, CA).   
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2.15 Cell-Cell Adhesion Assay 
 
Cell-cell adhesion was assayed using a dispase assay with minor modifications (Hobbs et 
al, 2011).  Cells were allowed to grow to confluency and then treated as indicated.  
Following treatment, the cells were washed with PBS- and incubated with Dispase II (2.4 
Units/mL, Roche Diagnostics, Indianapolis, IN) at 37°C for 30 minutes.  Following 
detachment from the culture plate, the cells were spun into a pellet, and then resuspended 
in PBS-.  The number of single cells in each sample was counted using a hemocytometer.  
The cells were spun down again and resuspended in 0.25% Trypsin.  Following 10 
minutes at 37°C, the number of total cells was counted using the hemocytometer.  
Percent single cells were calculated by dividing the number of single cells per sample by 
the number of total cells.  Three counts were taken per well for both the single and total 
cell counts.  Data is represented as mean % single cells ± standard deviation. 
 
2.16 siRNA Transfection 
 
Fyn siRNA (cat # SC29321), GATA3 (cat # SC29331), Lef-2 (cat # SC35804) and 
control siRNA (cat # SC37007) with no significant homology to the human transcriptome 
were obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, CA).  β-catenin siRNA 
was obtained from Cell Signaling (cat # 6225, Danvers, MA).  To transfect 325,000 
cells/well in a 6 well plate 6 μL Lipofectamine transfection reagent (Invitrogen, Grand 
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Island, NY) was mixed with 10 μL of 10 μM siRNA and 300 μL Opti-MEM/well.  
Knockdown was assessed 48-72 hours following transfection. 
 
2.17 Migration Assay 
 
Migration assays were performed using a 24-well HTS Multiwell Insert System (BD 
Falcon, San Jose, CA).  4 x 105 cells were seeded in serum-free DMEM into the upper 
chamber of each well and DMEM with 10% fetal bovine serum was added to the lower 
chamber.  Following 6 hours of incubation at 37°C to allow attachment Dasatinib was 
added to the upper and lower chamber of each well.  Cells were allowed to migrate for 24 
hours, then were fixed in 16% formaldehyde and stained with 0.05% crystal violet.  Cell 
counts from one visual field in three separate wells were averaged with error bars 
denoting standard deviation.   
 
2.18 Immunofluorescence and Quantitation 
 
Cells were grown on glass coverslips or cytospun onto slides, followed by fixation with 
4% paraformaldehyde and permeabilization with 0.1% Triton X-100.  Following fixation, 
the cells were blocked with 5% normal goat serum and then stained with Rhodamine-
phalloidin (100 nM, PHDR1, Cytoskeleton Inc., Denver, CO), α-catenin (CS-7894 Cell 
Signaling Technology Inc., Danvers, MA), β-catenin (SC-7963 Santa Cruz 
68 
 
 
 
Biotechnology Inc., Dallas, TX) or p120catenin (SC-13957 Santa Cruz Biotechnology 
Inc., Dallas, TX) and DAPI (0.1 μg/ml).  Following antibody staining, secondary 
antibodies conjugated to AlexaFluor 488 were applied and nuclei were stained with 
DAPI.  Microscopy and photography were performed on an Olympus AX80 microscope 
(Olympus Corporation, Center Valley, PA) with a QImaging Retiga 4000R CCD camera 
(QImaging, Surrey, BC, Canada) and the images were colorized and merged using Adobe 
Photoshop 6.0.  Quantitation of Rhodamine-phalloidin staining was performed by 
quantitating the fluorescence in three fields of equal area in the same image divided by 
the number of nuclei in each field.  Data is represented as mean fluorescence intensity/# 
nuclei ± standard deviation.   
 
2.19 Mouse Study  
 
Thirty-six SKH1 (Charles River, Chicago, IL) female 4-week old mice were divided into 
three groups of twelve and allowed to acclimate for 2 weeks.  Following acclimation, the 
mice were exposed to increasing doses of UVB three times a week from two Kodacel-
filtered FS20T12/UVB bulbs (National Biological, Beachwood, OH).  The doses began at 
30 mJ/cm² and were increased by 25% each week up to 150 mJ/cm².  Immediately 
following each UV exposure, the mice were topically treated with 200 μL of acetone, 
acetone with 10 nmole Dasatinib or acetone with 100 nmole Dasatinib.  There was no 
measurable difference in mouse weight between treatment groups.  After twenty-three 
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weeks of UV exposure, the mice were allowed to recover for a week and then were 
euthanized using CO2 gas.  Tumors were recovered and processed for analysis.  H&E 
staining was performed by the Pathology Histology Core at Loyola University Chicago.  
Assessment of tumor type from coded slides was performed by a board-certified 
dermatopathologist (Kelli A. Hutchens, MD).  All experiments were approved by the 
Loyola University Chicago Institutional Animal Care and Use Committee. 
 
2.20 Statistical Analysis 
 
To determine whether differences in generated data were significant, Student’s T-Tests  
were performed.  These T-Tests were calculated on unpaired data with two tails.   
To determine whether Dasatinib treatment resulted in a significant difference in the  
differentiation status of UVB-induced tumors a Fisher’s Exact Test was used. 
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CHAPTER III 
REGULATION OF FYN EXPRESSION 
IN HUMAN cSCC 
 
3.1 Abstract 
 
Fyn over-expression has been identified in cSCC, glioblastoma multiforme, head and 
neck squamous cell carcinoma, melanoma, sarcomas, lymphoma, breast, pancreatic and 
prostate cancer (Zhao et al, 2009, Saito et al, 2010, Ban et al, 2008, Lu et al, 2009, 
Posadas et al, 2009, Talantov et al, 2005, Palomero et al, 2014, Takayama et al, 1993, 
Martin et al, 2010).  In fact, the majority of human carcinomas contain upregulated SFK 
activity when compared to corresponding non-neoplastic tissue (Zhao et al, 2009).  
Despite the recurring nature of Fyn over-expression, the mechanism driving Fyn 
transcription and translation has only been studied at length in chronic myelogenous 
leukemia (CML), where Gao et al. found that BCR-ABL mediated reactive oxygen 
species (ROS) production drove Fyn expression through the transcription factors Egr1 
and Sp1 (Gao et al, 2009).  The signaling pathway regulating Fyn over-expression in 
other tumor types has not been reported, and may overlap or diverge from these findings 
in leukemic white blood cells.  In this study, we established a cell culture system where 
Ras-transformed HaCaT cells (a non-transformed, immortalized human keratinocyte cell 
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line) have selectively upregulated Fyn expression.  Using this model we identified a 
region of the FYN promoter necessary for Fyn upregulation, as well as putative 
transcription factors that may bind to this site in vivo.   
 
3.2 qPCR Analysis of SFK Expression  
 
Activating mutations in the Ras gene have been detected in 58% of human cSCCs 
(Pierceall et al, 1991), suggesting Ras is a common oncogene in these malignancies.  
Following the stable introduction of constitutively active H-Ras(G12V) to HaCaT cells 
(Yadav and Denning, 2011) we used RT-qPCR to measure expression levels of all 
members of the SFK family.  Only SRC, FYN, YES and LYN were expressed at detectable 
levels; expression levels of LCK, FGR, HCK and BLK were not detectable (Figure 6, data 
not shown).  FYN mRNA was upregulated over 200-fold in HaCaT-Ras cells (stably 
express H-Ras(G12V)) compared with HaCaT cells, while expression levels of SRC, YES 
and LYN remained unchanged (Figure 6).  Two isoforms of the Fyn protein, Fyn(B) and 
Fyn(T), are differentially expressed in the brain and T-cells but are expressed at similar 
levels in other tissues.  These isoforms arise through alternative splicing of exon 7 within 
the SH2-linker region of the FYN gene (Brignatz et al, 2009, Goldsmith, Hall and 
Atkinson, 2002).  We measured expression of FYN(B) and FYN(T) in our parental HaCaT 
and HaCaT-Ras cell lines using RT-qPCR and splice isoform-specific primers.  In HaCaT 
cells, the ratio of FYN(B) to FYN(T) mRNA was 7.4, indicating that FYN(T) was the 
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predominant isoform of Fyn expressed (Figure 7).  However, in the HaCaT-Ras cells, 
which have much higher levels of overall Fyn expression, the ratio of FYN(B) and 
FYN(T) mRNA was nearly equal to 1, indicating that expression of both isoforms was 
upregulated (Figure 7). 
 
RT-qPCR analysis of SFK expression in HaCaT-Ras cells indicated that FYN expression 
was selectively upregulated (Figure 6).  Increased mRNA levels may be due to increased 
activity at the FYN promoter, a transcriptional mechanism, or it may be due to increased 
stability of the FYN mRNA transcript, a translational mechanism.  We introduced a 
luciferase reporter plasmid containing a 2 kb segment of the FYN promoter (referred to as 
pFyn2000) into HaCaT and HaCaT-Ras cells and measured luciferase expression levels 
as an indicator of transcriptional activity at the FYN promoter.  HaCaT-Ras cells had 10x 
higher levels of luciferase activity, indicating FYN mRNA levels were upregulated 
through a transcriptional, and not translational, mechanism (Figure 8).  Previous studies 
have shown that FYN expression is upregulated by the production of reactive oxygen 
species (ROS) (Gao et al, 2009).  Additionally, many of the oncogenic functions of Ras 
are regulated by the ability of Ras to drive ROS production (Hole et al, 2010).  Following 
the introduction of pFyn2000 to HaCaT and HaCaT-Ras cells, we measured whether 
exposure to N-Acetyl-Cysteine (NAC), a free radical scavenger, reduced FYN expression 
levels in HaCaT-Ras cells.  Treatment with the anti-oxidant NAC in culture did not 
reduce FYN expression in either the HaCaT or HaCaT-Ras cells, suggesting that FYN 
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expression was regulated by a different mechanism than that defined by Gao et al. (Figure 
8) (Gao et al, 2009).   
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Figure 6: FYN Expression is Selectively Upregulated in HaCaT-Ras Cells 
Total RNA was isolated from HaCaT and HaCaT-Ras cells and analyzed for SFK 
RNA by RT-qPCR.  RNA levels were normalized to β-actin.  Data shown is a 
representative experiment that was performed in triplicate. 
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Figure 7: FYN(B) and FYN(T) are Both Upregulated in HaCaT-Ras Cells 
Total RNA was isolated from HaCaT and HaCaT-Ras cells and analyzed for 
FYN(B) and FYN(T) RNA by RT-qPCR.  RNA levels were normalized to 
GAPDH.  Data is expressed as a ratio of relative FYN(B) to FYN(T) mRNA levels.  
Data shown is a representative experiment that was performed in duplicate.  
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Figure 8: FYN Promoter Activity is Not Reduced By ROS Depletion 
pFyn2000, a plasmid containing 2 kb of the FYN promoter in front of a firefly 
luciferase gene, and pRL-TK were transiently co-transfected in HaCaT and 
HaCaT-Ras cells.  5mM N-Acetyl-Cysteine (NAC) was added with the DMEM 
media prior to transfection.  After 48 hours luciferase activity in cell lysates was 
measured.  Data shown is a representative experiment that was performed in 
triplicate. 
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3.3 Analysis of the FYN Promoter Using Luciferase Reporter Plasmids 
 
To identify potential transcription factors mediating FYN upregulation, we first created a 
series of luciferase reporter plasmids containing segments of the FYN promoter.  The 
largest plasmid contained 2 kb of the FYN promoter (pFyn2000), and the other plasmids 
each contained progressively smaller segments of this sequence, with the smallest 
segment beginning 50 bases before the FYN transcription start site (pFyn50) (Figure 9a).  
Introduction of the full length (2 kb) FYN reporter plasmid (as shown in Figure 8) 
resulted in higher luciferase expression in HaCaT-Ras cells as compared to HaCaT cells, 
reaffirming our qPCR data (Figure 6 & 9b).  Additionally, the region -100 to -50 bases 
before the transcription start site was proven necessary for FYN upregulation in HaCaT-
Ras cells, as loss of this region resulted in decreased luciferase expression (Figure 9b).   
 
Careful analysis of the region of interest in the FYN promoter using online transcription 
factor prediction software such as TFSearch, PROMO, TFBind and TFSiteScan identified 
several transcription factors that were predicted to bind within an approximately 20 base 
region -65 to -85 base pairs before the transcription start site.  Following mutation of the 
dinucleotide GA sequence located -74 bases upstream of the transcription start site to a 
CT in the pFyn2000 plasmid (Figure 10a), FYN reporter activity in the HaCaT-Ras cells 
was reduced, indicating this sequence was necessary for FYN over-expression (Figure 
10b).  Furthermore, when nuclear cell lysate from HaCaT and HaCaT-Ras cells was 
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allowed to bind to a double-stranded oligonucleotide corresponding to the region of 
interest (-63 to -83 bases upstream of the transcription start site) in the FYN promoter, 
electrophoretic mobility shift assay (EMSA) analysis showed a greater amount of binding 
in the HaCaT-Ras lysate than the HaCaT lysate (Figure 11).  Incubation with an 
oligonucleotide containing a GACT mutation at the -74 base site (Figure 10a) resulted 
in loss of binding when incubated with HaCaT-Ras cell lysate, as can be seen by loss of 
the band denoted with an asterisk (Figure 11).  Despite the remaining presence of 
nonspecific bands, these results reaffirmed the importance of this site in FYN gene 
regulation (Figure 11).    
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Figure 9: The -100 to -50 Region of the FYN Promoter is Necessary for FYN 
Expression in HaCaT-Ras Cells 
 
A. Schematic of the luciferase reporter constructs created to identify regions of 
the human FYN promoter necessary for FYN expression.  Segments corresponding 
to regions beginning -2000 bases down to -50 bases before the FYN transcription 
start site were ligated into the pGL3-Basic plasmid.  Figure courtesy of Dr. 
Mitchell F. Denning.  
B. FYN reporter plasmids were transiently co-transfected with pRL-TK into 
HaCaT and HaCaT-Ras cells.  pGL3-Basic was used as a negative control, as it 
does not contain any part of the FYN promoter.  Luciferase levels were measured 
48 hours following transfection.  Data shown is a representative experiment that 
was performed in triplicate. 
 pFyn1000 
pGL3-Basic 
pFyn2000 
pFyn500 
pFyn100 
pFyn50 
-100 bp 
-50 
bp 
pFyn1000 -1000 bp 
-500 
bp 
pFyn500 
pFyn100 
pFyn50 
-2000 
bp 
pFyn2000 
 
 
LUC 
LUC 
LUC 
LUC 
LUC 
 
80 
 
 
 
A. 
 
 
 
B. 
 
 
 
Figure 10: Mutation of the GA Sequence in the FYN Promoter Reduces FYN 
Expression in HaCaT-Ras Cells 
 
A. Schematic of the FYN promoter region of interest between -100 and -50 bases 
before the transcription start site.  Transcription factors with high likelihood of 
binding are shown.  The pFyn2000-mutant reporter plasmid was created by 
mutating the GA sequence at -74 to CT (*).  Figure courtesy of Dr. Mitchell F. 
Denning 
B. pFyn2000 or pFyn2000-mutant was transiently co-transfected with pRL-TK 
into HaCaT and HaCaT-Ras cells.  Luciferase levels were measured 48 hours 
following transfection.  Data shown is a representative experiment that was 
performed in triplicate.  
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Figure 11: EMSA Analysis of Binding to the FYN Promoter 
 
Oligonucleotides corresponding to the region of interest (-63 to-83 bases upstream 
of the transcription start site) in the FYN promoter, as well as the mutated region 
of interest (-74GACT), were incubated with nuclear cell lysates from HaCaT 
and HaCaT-Ras cells and then were run on a 4% agarose gel to detect binding.  H 
corresponds to HaCaT cell lysate and R corresponds to HaCaT-Ras cell lysate.  
Unbound oligonucleotide was run on the left as a control.  Free probe is 
designated at the bottom.  The band lost upon incubation with the mutant probe is 
indicated by an *.  Data shown is a representative experiment that was performed 
in triplicate.   
 
 
 
Free Probe 
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3.4 Transcription Factor Expression Levels in HaCaT and HaCaT-Ras Cells 
 
 
Using the online programs TFSearch, PROMO, TFBind and TFSiteScan, we identified 
several transcription factors predicted to bind to the region of interest -65 to -85 bases 
before the transcription start site in the FYN promoter (Figure 10a).  To determine if any 
of these factors were upregulated in the HaCaT-Ras cells, we used RT-qPCR to measure 
expression levels of the GATA family, TCF4 and LEF1 genes.  Expression levels of 
GATA1, GATA2, GATA3 and TCF4 mRNAs were not significantly upregulated in the 
HaCaT-Ras cells as compared to the parental HaCaT cells (Figures 12 & 13).  However, 
expression levels of LEF1 mRNA were increased over 2000-fold in the HaCaT-Ras cell 
line, suggesting that this transcription factor may be responsible for high Fyn expression 
in HaCaT-Ras cells (Figure 13). 
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Figure 12: GATA1, 2 and 3 Expression in HaCaT and HaCaT-Ras Cells 
 
Total RNA was isolated from HaCaT and HaCaT-Ras cells and analyzed for 
GATA1, GATA2 and GATA3 RNA by RT-qPCR.  RNA levels were normalized to 
GAPDH.  Data shown is a representative experiment that was performed in 
duplicate.   
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Figure 13: TCF4 and LEF1 Expression in HaCaT and HaCaT-Ras Cells 
 
Total RNA was isolated from HaCaT and HaCaT-Ras cells and analyzed for 
TCF4 and LEF1 RNA by RT-qPCR.  RNA levels were normalized to GAPDH.  
Data shown is a representative experiment that was performed in duplicate.    
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3.5 Analysis of Transcription Factor Binding at the Fyn Promoter 
 
Based on the results of our FYN promoter analysis (Figure 9a) and RT-qPCR data (Figure 
13), we next performed ChIP to detect binding of any of these potential transcription 
factors to the FYN promoter.  We also assessed binding levels of β-catenin at this site, as 
β-catenin is an essential binding partner of the TCF family and is necessary for regulation 
of gene expression.  Experiments performed in triplicate indicated that higher levels of 
Lef-1 and β-catenin bound to the FYN promoter in HaCaT cells as compared to HaCaT-
Ras cells (Figure 14).  Similarly, experiments performed in triplicate indicated that higher 
levels of GATA-2 and GATA-3 bound to the FYN promoter in HaCaT cells as compared 
to HaCaT-Ras cells (Figure 15).  The nonspecific mouse IgG negative controls in both 
experiments resulted in low detection of binding.  Despite the fact that all of the binding 
levels were above the mouse IgG control, the percent input for Lef-1, β-catenin, GATA-2 
and GATA-3 was very low (< 1% input), suggesting the difference in binding between 
HaCaT and HaCaT-Ras cells may not be biologically meaningful.   
 
Using EMSA we assessed the ability of antibodies corresponding to the transcription 
factors of interest to alter binding of the cell lysate to the FYN promoter oligonucleotide.  
Following incubation of the HaCaT-Ras cell nuclear lysate and the -63 to -83 Fyn 
oligonucleotide with an antibody against Lef-1, the previously detected band indicating 
association between the lysate and oligonucleotide was lost, suggesting the Lef-1 
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antibody was interfering with this interaction and Lef-1 may be the transcription factor 
mediating FYN transcriptional regulation (Figure 16).  Incubation with antibodies against 
GATA-2 and GATA-3 did not alter the association between the Fyn oligonucleotide and 
nuclear cell lysate (Figure 16).  
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Figure 14: ChIP Analysis of Lef-1 and β-Catenin Binding to the FYN 
Promoter 
 
ChIP assay was performed on lysates from formaldehyde cross-linked HaCaT and 
HaCaT-Ras cells using antibodies against Lef-1 and β-catenin.  Precipitated FYN 
promoter DNA was quantitated by RT-qPCR.  Precipitation with mouse IgG is 
shown as a negative control.  Data shown is a representative experiment that was 
performed in triplicate.  
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Figure 15: ChIP Analysis of GATA-2 and GATA-3 Binding to the FYN 
Promoter 
 
ChIP assay was performed on lysates from formaldehyde cross-linked HaCaT and 
HaCaT-Ras cells using antibodies against GATA-2 and GATA-3.  Precipitated 
FYN promoter DNA was quantitated by RT-qPCR.  Precipitation with mouse IgG 
is shown as a negative control.  Data shown is a representative experiment that 
was performed in triplicate.    
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Figure 16: EMSA Analysis of Antibody Interference with Binding to the FYN 
Promoter 
 
Oligonucleotides corresponding to the region of interest in the FYN promoter (-63 
to -83 bases upstream of the transcription start site) were incubated with nuclear 
lysates from HaCaT and HaCaT-Ras cells as well as antibodies against the 
predicted transcription factors.  The lysates were then run on a 4% agarose gel to 
detect binding.  Unbound oligonucleotide was run on the left as a control.  Data 
shown is a representative experiment that was performed in triplicate.    
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3.6 Assessment of Fyn Expression Following Knockdown of Transcription Factors 
 
Following the EMSA analysis of transcription factor binding, we used siRNA to knock 
down Lef-1 expression (Figure 17a).  72-hours after siRNA transfection we measured 
FYN expression levels in HaCaT and HaCaT-Ras cells using RT-qPCR (Figure 17b).  
Despite the fact that LEF1 mRNA levels were reduced over 80%, FYN expression levels 
were not decreased by reduced LEF1 expression (Figure 17b).  However, a careful 
analysis of the literature suggested that other TCF family members may replace Lef-1 
activity, maintaining transcriptional regulation of their target genes (Staal and Clevers, 
2000).  To address this potential complicating factor we then knocked down β-catenin, a 
required binding partner of the TCF family of transcription factors.  72-hours after 
transfection with β-catenin siRNA in HaCaT-Ras cells FYN expression levels were not 
decreased (Figure 18).  
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B.  
 
 
Figure 17: FYN Expression is Not Reduced Following Lef-1 Knockdown in 
HaCaT and HaCaT-Ras Cells 
 
A. HaCaT and HaCaT-Ras cells were transfected with siRNA against Lef-1.  72 
hours later total RNA was isolated and analyzed for LEF1 RNA by RT-qPCR.  
RNA levels were normalized to GAPDH.  Data shown is a representative 
experiment that was performed in duplicate.  
B.  HaCaT and HaCaT-Ras cells were transfected with siRNA against Lef-1.  72 
hours later total RNA was isolated and analyzed for FYN RNA by RT-qPCR.  
RNA levels were normalized to GAPDH.  Data shown is a representative 
experiment that was performed in duplicate.  
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Figure 18: FYN Expression is Not Decreased Following β-catenin 
Knockdown in HaCaT-Ras Cells 
 
HaCaT-Ras cells were transfected with siRNA against β-catenin.  72 hours later 
total RNA was isolated and analyzed for βCATENIN and FYN RNA by RT-qPCR.  
RNA levels were normalized to GAPDH.  Data shown is a representative 
experiment that was performed in duplicate.  
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3.7 Summary 
 
Previous findings concerning Fyn over-expression in BCR-ABL transformed cells 
indicated that ROS and the transcription factors Sp1 and Egr1 regulated Fyn levels.  
However, in our system, where increased Ras activity is upstream of Fyn expression, 
treatment with NAC did not decrease Fyn expression levels (Figure 8).  Instead, we 
identified a region -50 to -100 bases upstream of the transcription start site as critical for 
Fyn regulation and further identified two bases that, when mutated, significantly reduce 
Fyn expression (Figures 9b & 10b).  Binding analyses studies indicated that the 
transcription factor Lef-1 was likely regulating this induction of Fyn expression (Figure 
16).  However, in vivo assays such as ChIP and siRNA knockdown did not support our in 
vitro results (Figures 14, 17 & 18).     
 
  
  
94 
 
CHAPTER IV 
EFFECT OF DASATINIB ON 
HACAT AND HACAT-RAS 
CELL PHENOTYPE 
 
4.1 Abstract 
 
Fyn upregulation has been implicated in cellular transformation and oncogenesis in many 
tissues (Zhao et al, 2009, Calautti et al, 1995, Tu et al, 2008).  Increased Fyn activity in 
oral SCC cell lines is sufficient to induce a transition from an epithelial to a mesenchymal 
phenotype, resulting in an increased migratory capacity (Lewin et al, 2010).  In the 
murine epidermis, over-expression of constitutively active Fyn(Y528F) results in 
downregulation of the tumor suppressors Notch1 and p53, ultimately inducing the 
formation of keratotic tumors and AKs that progress to SCCs (Zhao et al, 2009).  
Increased Fyn activity has also been shown to increase cellular proliferation and inhibit 
apoptosis (Singh et al, 2012, Kim et al, 2010).  Additionally, Fyn expression is 
upregulated in HaCaT cells following the introduction of oncogenic H-Ras, increasing 
the migratory and invasive capacity of the cells (Yadav and Denning, 2011).  Due to 
Fyn’s predicted role as an oncogene, inhibition of Fyn activity may be an effective 
therapy in the treatment of cSCC. 
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To inhibit Fyn activity, we treated the HaCaT and HaCaT-Ras cells with Dasatinib, a 
small molecule tyrosine kinase inhibitor that binds to the ATP-binding site to inhibit SFK, 
BCR-ABL, EphA2, PDGFR and c-Kit activity (Aguilera and Tsimberidou, 2009).  
Dasatinib was chosen to inhibit Fyn because it is an orally administered, FDA-approved 
anti-cancer drug with known pharmacology and side effects.  Following Dasatinib 
treatment we measured cell viability, proliferation, cell cycle distribution, apoptosis and 
autophagy.  Although Dasatinib treatment did cause a reduction in cell viability, it did not 
alter cell viability in the transformed HaCaT-Ras cells to a greater extent than in the 
parental HaCaT cells (Figure 23). 
 
4.2 Increased Fyn Protein is Sufficient to Induce the Epithelial to Mesenchymal 
Transition (EMT) 
 
 
Previous studies in oral SCC have shown that Fyn activity is sufficient to drive a switch 
from an epithelial to a mesenchymal morphology, commonly known as the epithelial to 
mesenchymal transition or EMT (Lewin et al, 2010).  Simply put, EMT is a biological 
process where a polarized epithelial cell assumes a more migratory, mesenchymal 
phenotype.  Although this change has many functions in normal physiological processes 
such as embryonic development and wound healing, it is also understood to be an 
important step in the progression of malignancies (Kalluri and Weinberg, 2009b).  Using 
Western blot techniques, we assessed E-cadherin, cytokeratin and vimentin expression, 
all markers used to asses EMT.  HaCaT-Ras cells had decreased protein levels of E-
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cadherin and pan-cytokeratin and increased levels of vimentin compared to parental 
HaCaT cells, which in combination with their small, stellate appearance indicated the 
HaCaT-Ras cells had undergone EMT (Figures 19 & 20).  To test if Fyn over-expression 
was sufficient to induce EMT in HaCaT cells, we stably introduced active Fyn(I338T) to 
HaCaT cells (HaCaT-Fyn cells) by retroviral transduction, resulting in a similar level of 
Fyn expression when compared to the HaCaT-Ras cells.  The introduction of active Fyn 
reduced E-cadherin and cytokeratin levels and increased vimentin expression, indicating 
that Fyn was sufficient to induce EMT in HaCaT cells (Figure 19). 
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Figure 19. Introduction of Active Ras or Fyn is Sufficient to Induce EMT 
Protein levels of Fyn and the EMT markers E-cadherin, pan-cytokeratin and 
vimentin were measured using a Western blot on lysates from HaCaT, HaCaT-
Fyn and HaCaT-Ras cells.  β-actin was used as a loading control.  Data shown is a 
representative experiment that was performed in triplicate.   
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4.3 Dasatinib Treatment Inhibits Fyn and Alters Cell Morphology But Does Not 
Reverse EMT 
 
 
Following 24 hours of Dasatinib exposure, HaCaT cells maintained their epithelial 
phenotype while HaCaT-Ras and HaCaT-Fyn cells underwent a marked change in 
appearance (Figure 20).  HaCaT-Ras and HaCaT-Fyn cells normally grow in a poorly 
adherent, even distribution in the cell culture plate, but Dasatinib treatment caused both 
cell types to form tight cell aggregates that frequently detached from the plate.  To ensure 
that Dasatinib treatment was inhibiting Fyn activity we performed a Luminex Milliplex 
Map 8-Plex Human Src Family Kinase Phosphoprotein assay assessing the activating 
phosphorylation status of all SFKs.  Phosphorylation of the activating tyrosine (Y418) on 
Fyn, as well as other SFKs, was significantly inhibited by 50-100 nM Dasatinib in 
HaCaT-Ras cells (p<0.01) (Figure 21).  Following the change in cellular morphology 
caused by Dasatinib treatment, we assessed whether EMT was being reversed through 
SFK inhibition.  Using Western blot techniques we again measured E-cadherin, 
cytokeratin and vimentin expression.  Expression of E-cadherin was not restored and 
vimentin expression was not reduced, suggesting Dasatinib treatment is not sufficient to 
reverse EMT (Figure 22).  To determine the mechanism driving EMT in Ras and Fyn-
transformed cells, we used RT-qPCR to measure mRNA levels of three EMT master 
regulators: Slug, Snail and Twist.  Slug was significantly upregulated in HaCaT-Fyn 
(p<0.01) and HaCaT-Ras cells (p<0.005).  Snail was also significantly upregulated in the 
HaCaT-Fyn (p<0.01) and HaCaT-Ras (p<0.001) cells.  However, Twist was the most 
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markedly upregulated, with an over 45-fold induction in both the HaCaT-Fyn (p<0.005) 
and HaCaT-Ras (p<0.001) cells (Figure 23).  Following 24 hours of 1 μM Dasatinib 
treatment, expression levels of Twist were not reduced to levels similar to those seen in 
parental HaCaT cells, again suggesting Dasatinib treatment is not sufficient to reverse 
EMT (Figure 23).   
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Figure 20. Dasatinib Treatment Results in a Morphology Change in HaCaT-
Fyn and HaCaT-Ras Cells But Not HaCaT Cells 
Phase-contrast pictures of HaCaT, HaCaT-Fyn and HaCaT-Ras cells untreated or 
following 24 hours of 0.1 µM or 1.0 µM Dasatinib treatment.  HaCaT cells 
maintain their cobblestone epithelial morphology, while Dasatinib exposed 
HaCaT-Fyn and HaCaT-Ras cells form aggregates in the culture dish.  
 
 
 
 
 
101 
 
 
 
 
 
 
 
 
Figure 21. Dasatinib Treatment Inhibits SFK Activity in HaCaT-Ras Cells 
Levels of phosphorylation at the SFK activation site (Y418) for all SFKs were 
assessed using a Milliplex Map 8-Plex Human Src Family Kinase Phosphoprotein 
kit and a Luminex plate reader.  Significant reduction of Fyn activity was induced 
by 0.05 μM Dasatinib treatment (*p<0.01) and 0.1 μM Dasatinib treatment 
(#p<0.01).  Data shown is a representative experiment that was performed in 
duplicate. 
 
  
 
 
Untreated 
0.05μM Dasatinib 
 0.1μM Dasatinib 
* 
* 
# 
# 
 
102 
 
 
 
 
 
 
 
 
   
 
 
 
 
     
  
          
    
  
 
 
Figure 22. Treatment with Dasatinib for 24 Hours Does Not Reverse EMT 
 
Following treatment with 1 μM Dasatinib for 24 hours, protein levels of Fyn and 
the EMT markers E-cadherin and vimentin were measured using Western blot 
techniques on lysates from HaCaT, HaCaT-Fyn and HaCaT-Ras cells.  β-actin 
was used as a loading control.  Data shown is a representative experiment that 
was performed in duplicate.  
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Figure 23: Twist is Upregulated In HaCaT-Fyn and HaCaT-Ras Cells and 
Dasatinib Treatment Does Not Restore Expression to Levels Seen in HaCaT 
Cells 
 
Total RNA was isolated from HaCaT, HaCaT-Fyn and HaCaT-Ras cells 
following no treatment or 24 hours in 1 μM Dasatinib and analyzed for Snail, 
Slug and Twist RNA by RT-qPCR.  RNA levels were normalized to GAPDH.  
Data shown is a representative experiment that was performed in triplicate. 
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4.4 Dasatinib Treatment Reduces Cell Viability and Cellular Proliferation to a 
Similar Extent in HaCaT and HaCaT-Ras Cells 
 
 
 
Fyn activity has been linked to increased cellular proliferation and reduced apoptosis 
(Singh et al, 2012, Kim et al, 2010, Chen et al, 2011).  Following Dasatinib treatment and 
Fyn inhibition, HaCaT-Ras cells undergo a dramatic change in cellular morphology, 
detaching from the culture dish and forming aggregates that float in the media (Figure 
20).  It is possible that this change in appearance was due to a decrease in cell viability 
following Dasatinib treatment.  To assess changes in cell viability, we treated the cells 
with Dasatinib for 24 hours, then stained the attached and floating cells with Trypan Blue 
or removed the Dasatinib from the culture environment and replated the cells.  Similar 
levels of positive Trypan Blue staining (i.e. apoptotic cells) were seen in the treated and 
untreated HaCaT and HaCaT-Ras cells, and both cell types grew as usual following 
replating in Dasatinib-free media, indicating that Dasatinib was not inducing cell death 
(data not show).  We also assessed Dasatinib’s ability to decrease cell viability by 
introducing alamarBlue to our cell culture medium.  AlamarBlue is a cell health indicator 
composed of resazurin, a blue compound that when taken up by a healthy or viable cell is 
reduced to resorufin, a red compound.  Therefore, by measuring fluorescence following 
incubation with alamarBlue we can directly measure the cell population’s ability to 
proliferate, maintain normal metabolism and survive after Dasatinib treatment.  
Following 48 hours in 0.1 μM or 1 μM Dasatinib cell viability was comparably reduced 
in both the HaCaT and HaCaT-Ras cells (Figure 24).  Similar results were found 
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following Dasatinib treatment for 24 and 72 hours (data not shown).  We also measured 
cellular proliferation by quantitating the amount of DNA present in the cell population 
following Dasatinib treatment, and did not measure a significant reduction in cellular 
proliferation in either the HaCaT or HaCaT-Ras cells (Figure 25).  We also measured 
cellular proliferation through the incorporation of radioactive 3H-thymidine into DNA 
strands during S-phase following Dasatinib treatment.  Again, we did not find a 
significant reduction in cellular proliferation following 24 hours in either 0.1 μM or 1 μM 
Dasatinib (Figure 26).  Finally, we assessed cell cycle progression in untreated and 
Dasatinib treated HaCaT and HaCaT-Ras cells by staining the cells with propidium 
iodide (PI), a fluorescent intercalating agent that binds to DNA to give a stoichiometric 
measure of the amount of DNA present in the cell.  Therefore, cells in the S phase of the 
cell cycle will have a greater DNA content than cells in G1 and through this method the 
different phases of the cell cycle can be identified.  Treatment with 0.1 or 1 μM Dasatinib 
for 24 hours slightly increased the number of HaCaT cells in the sub-G0 phase (apoptotic 
cells), but otherwise did not alter cell cycle distribution in either the HaCaT or HaCaT-
Ras cells (Figure 27).   
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Figure 24: Treatment with Dasatinib Reduced Cellular Viability to a Similar 
Extent in both HaCaT and HaCaT-Ras Cells 
 
Following treatment with either 0.1 μM or 1 μM Dasatinib for 48 hours 
alamarBlue was added to the cell culture medium and allowed to incubate for 2 
hours.  Fluorescence was then measured to determine the amount of alamarBlue 
that had been metabolized by viable cells.  Data shown is a representative 
experiment that was performed in triplicate. 
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Figure 25: Treatment with Dasatinib Did Not Reduce Cellular Proliferation 
in Either HaCaT or HaCaT-Ras Cells 
 
Following treatment with either 0.1 μM or 1 μM Dasatinib for 24 hours DNA was 
stained with the fluorescent dye Hoechst 33458 and quantitated.  Data shown is a 
representative experiment that was performed in triplicate. 
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Figure 26: Treatment with Dasatinib Did Not Reduce Cellular Proliferation 
in Either HaCaT or HaCaT-Ras Cells 
 
Following treatment with either 0.1 μM or 1 μM Dasatinib and concurrent 
incubation with 3H-thymidine for 24 hours, incorporation of radioactive 
thymidine into the DNA was measured.  Data is expressed as counts per minute 
(cpm).  Data shown is a representative experiment that was performed in 
triplicate. 
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Figure 27: Treatment with Dasatinib Did Not Alter Cell Cycle Distribution in 
HaCaT-Ras Cells 
 
Following treatment with either 0.1 μM or 1 μM Dasatinib for 24 hours DNA was 
stained with propidium iodide and quantitated using flow cytometry.  Data shown 
is a representative experiment that was performed in triplicate. 
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4.5 Dasatinib Treatment Induces Apoptosis to a Similar Extent in HaCaT and 
HaCaT-Ras Cells and Does Not Induce Autophagy 
 
 
 
Increased Fyn activity provides a protective effect against apoptosis and cell death 
through increased phosphorylation of Sam68 and expression of HnRNPA2B1 (Chen et al, 
2011).  Inhibition of Fyn, either directly using siRNA or by Dasatinib treatment, has also 
been shown to induce autophagy in T-cells, chronic lymphocytic leukemia, ovarian 
cancer and gliomas (Harr et al, 2010, Krause and Hallek, 2011, Le et al, 2010, Milano et 
al, 2009).  Based on these findings we assessed levels of apoptosis and autophagy in 
HaCaT and HaCaT-Ras cells following Dasatinib treatment.  To measure apoptosis we 
stained the cells with Annexin V-FITC and propidium iodide (Figure 28).  When cells are 
in early apoptosis they begin to expose phosphatidylserine on the external cytoplasmic 
membrane.  Annexin V-FITC binds to the external phosphatidylserine and emits a green 
fluorescence.  When cells are in late apoptosis or are necrotic, the integrity of the 
cytoplasmic membrane is decreased, allowing the entry of PI, which binds to the DNA 
and emits a red fluorescence.  Through this staining technique populations of early and 
late apoptotic cells can be detected and measured.  Following 24 hours in 0.1 μM or 1 μM 
Dasatinib apoptosis was induced in both the HaCaT and HaCaT-Ras cells (Figure 28).  
However, there was no selective effect in the transformed HaCaT-Ras cells – both cell 
lines induced apoptosis at comparable levels (Figure 28).  Similar to apoptosis, autophagy 
is an alternative process of cell death involving targeted degradation of necessary cellular 
components (Glick, Barth and Macleod, 2010).  Acridine orange is a green fluorescent 
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molecule that accumulates in acidic organelles, where it becomes protonated and emits a 
red fluorescence.  Because autophagy involves the degradation of cellular components 
through the lysosomal pathway, large amounts of acridine orange become trapped in the 
acidified lysosome and can be detected by flow cytometry.  Dasatinib treatment did not 
induce autophagy in either the HaCaT or HaCaT-Ras cells following 24 hours of 
exposure (Figure 29).   
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Figure 28: Treatment with Dasatinib Induced Apoptosis to a Similar Extent 
in both HaCaT and HaCaT-Ras Cells 
 
Following treatment with either 0.1 μM or 1 μM Dasatinib for 24 hours cells were 
stained with Annexin V and propidium iodide.  Fluorescence was measured on a 
flow cytometer.  Data shown is a representative experiment that was performed in 
triplicate. 
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Figure 29: Treatment with Dasatinib Did Not Induce Autophagy in Either 
HaCaT or HaCaT-Ras Cells 
 
Following treatment with either 0.1 μM or 1 μM Dasatinib for 24 hours Acridine 
Orange was added to the cell culture plate and allowed to incubate for 20 minutes.  
Fluorescence was measured on a flow cytometer.  Data shown is a representative 
experiment that was performed in triplicate. 
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4.6 Dasatinib Treatment Increases Levels of Apoptosis in HaCaT Cells Following 
UVB Exposure 
 
 
 
Dasatinib treatment alone increased levels of apoptotic HaCaT cells less than 6% (Figure 
28).  These results were surprising, as Fyn activity is known to protect against apoptosis 
(Chen et al, 2011).  One would therefore expect inhibition of Fyn and the SFK family to 
significantly increase the amount of cell death present in the HaCaT and HaCaT-Ras 
cells.  We postulated that this effect may only be seen with the addition of another 
stressor, for example a genotoxic insult that is known to result in apoptosis in 
keratinocytes, UVB.  To accomplish this, we exposed HaCaT cells to 10 mJ/cm2 UVB 
and followed immediately with 1 μM Dasatinib treatment.  After 24 hours we assessed 
levels of early and late apoptotic cells using an Annexin-V/propidium iodide staining 
assay.  As seen previously, Dasatinib treatment alone resulted in a slight increase in 
apoptosis (Figure 28 & 30).  UVB exposure induced higher levels of total apoptosis, but 
Dasatinib treatment following UVB exposure resulted in significantly higher levels of 
apoptotic cells (p<0.01) (Figure 30).  These results suggest that Dasatinib has an additive 
effect, increasing the likelihood of a cell undergoing apoptosis following UVB exposure.   
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Figure 30: Treatment with Dasatinib Following UVB Exposure Resulted in 
Greater Levels of Apoptosis Then Either Treatment Alone 
 
Following exposure to 10mJ/cm2 UVB the cells were treated with 1 μM 
Dasatinib.  After 24 hours the cells were stained with Annexin V and propidium 
iodide.  Fluorescence was measured on a flow cytometer.  Levels of total 
apoptosis were significantly higher in the Dasatinib + UVB treated group than in 
the Dasatinib or UVB-alone groups (*p<0.01).  Data shown is a representative 
experiment that was performed in duplicate. 
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4.7 Summary 
 
Upregulation of Fyn expression, either directly or indirectly through the Ras oncogene, 
induces EMT in HaCaT cells (Figure 19).  Exposure of the HaCaT-Ras and HaCaT-Fyn 
cells to the SFK inhibitor Dasatinib drives a marked change in cell morphology, but does 
not reverse EMT, alter cell viability, proliferation or cell cycle distribution, or induce 
apoptosis or autophagy to a greater extent than that seen in the parental HaCaT cells 
(Figures 20, 22, 23, 24, 25, 26, 27, 28 & 29).  However, Dasatinib treatment immediately 
after UVB exposure results in greater cell death than either Dasatinib treatment or UVB 
exposure alone, suggesting an additive effect (Figure 30).  
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CHAPTER V 
DASATINIB INDUCES F-ACTIN AND  
ADHERENS JUNCTION FORMATION  
IN HACAT-RAS CELLS 
 
5.1 Abstract 
 
Fyn acts as an oncogene in murine epidermis and has been associated with cell-cell 
adhesion turnover and the induction of a migratory phenotype.  Inhibition of Fyn activity 
in HaCaT-Fyn and HaCaT-Ras cells, using either siRNA or the therapeutic SFK inhibitor 
Dasatinib, increased cell-cell adhesion through a rapid increase in the cortical F-actin 
cytoskeleton and reduced cellular migration (Figures 31, 32, 34, 36 & 38).  In Dasatinib-
treated HaCaT-Ras cells, F-actin colocalized with adherens junction proteins, suggesting 
that stable adherens junctions were mediating the increase in cell-cell adhesion (Figure 
40).  Inhibition of the Rho effector kinase ROCK blocked Dasatinib-induced F-actin and 
cell-cell adhesion, implicating relief of Rho GTPase inhibition as a mechanism of 
Dasatinib-induced cell-cell adhesion (Figure 41).  F-actin polymerization was a key 
initiator of cell-cell adhesion, as Dasatinib-induced cell-cell adhesion could be blocked 
by Cytochalasin D, an inhibitor of actin polymerization (Figure 44).  Conversely, 
inhibiting cell-cell adhesion with low Ca2+ media did not block Dasatinib-induced F-actin 
polymerization (Figure 45).  Together these results identify the promotion of actin-based 
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cell-cell adhesion as a newly described mechanism of action for Dasatinib, and suggest 
that Fyn inhibition may be an effective therapeutic approach in treating cSCC. 
 
5.2 Dasatinib Treatment Increases Cell-Cell Adhesion in HaCaT-Ras Cells and 
Inhibits Migration 
 
 
Because Fyn is oncogenic in keratinocytes (Zhao et al, 2009, Li et al, 2007) and its 
activity is sufficient to induce EMT, we evaluated the effects of the clinical SFK inhibitor 
Dasatinib on HaCaT, HaCaT-Ras and HaCaT-Fyn cells.  HaCaT-Ras and HaCaT-Fyn 
cells normally grow in a poorly adherent, even distribution in the cell culture plate, but 
Dasatinib caused both cell types to form tight cell aggregates that frequently detached 
from the plate (Figure 20).  The detachment was pronounced in areas of confluency that 
have extensive cell-cell contacts.  Using a quantitative cell-cell adhesion assay, we 
determined that 0.1 and 1 μM Dasatinib exposure for 24 hours decreased the percent of 
single cells in HaCaT-Fyn and HaCaT-Ras cells by over 6-fold, indicating Dasatinib 
treatment increased cell-cell adhesion (Figure 31).  Furthermore, Fyn inhibition using 
siRNA was sufficient to induce a 6-fold increase in cell-cell adhesion 72 hours following 
transfection in both HaCaT-Ras and HaCaT-Fyn cells, but did not increase cell-cell 
adhesion in HaCaT cells (Figure 32).  Fyn siRNA also induced cell-cell adhesion in 
MDA-MB-231 cells, a human breast cancer cell line with elevated Fyn (Figure 33) 
(Yadav and Denning, 2011).  Consistent with their EMT phenotype, both HaCaT-Fyn and 
HaCaT-Ras cells had enhanced migration compared to HaCaT cells, and Dasatinib 
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treatment significantly inhibited the migration of HaCaT-Fyn and HaCaT-Ras cells 
(p<0.001) (Figure 34).   
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Figure 31: Dasatinib Treatment Induces Cell-Cell Adhesion in HaCaT-Fyn 
and HaCaT-Ras Cells 
 
HaCaT, HaCaT-Fyn and HaCaT-Ras cell-cell adhesion was measured in untreated 
cells or following 24 hours of 0.1 µM or 1.0 µM Dasatinib treatment using a 
dispase assay.  Note that a low percentage of single cells corresponds to high cell-
cell adhesion.  Cell-cell adhesion was significantly increased in the HaCaT-Fyn 
and HaCaT-Ras cells following 0.1 μM Dasatinib treatment (*,%p<0.001) and 1.0 
μM Dasatinib (#,$p<0.001) treatment.  Data shown is a representative experiment 
that was performed in triplicate. 
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Figure 32: Fyn Knockdown Induces Cell-Cell Adhesion in HaCaT-Fyn and 
HaCaT-Ras Cells 
 
Cell-cell adhesion was measured 72 hours after transfection of HaCaT, HaCaT-
Fyn and HaCaT-Ras cells with control or Fyn siRNA.  The Western blot verifying 
Fyn knockdown is shown below.  Cell-cell adhesion was significantly increased 
in the HaCaT-Fyn cells (*p<0.01) and the HaCaT-Ras cells (#p<0.001) following 
Fyn knockdown.  Data shown is a representative experiment that was performed 
in duplicate.  
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Figure 33: Fyn Knockdown Induces Cell-Cell Adhesion in MDA-MB-231 
Cells 
 
Cell-cell adhesion was measured 72 hours after transfection with Fyn siRNA.  
Cell-cell adhesion was significantly increased in the MDA-MB231 cells 
(*p<0.05) following Fyn knockdown.  Data shown is a representative experiment 
that was performed in duplicate.  
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Figure 34: Dasatinib Treatment Inhibits Migration in HaCaT-Fyn and 
HaCaT-Ras Cells 
 
HaCaT, HaCaT-Fyn and HaCaT-Ras cells were untreated or treated with 0.1 µM 
or 1.0 µM Dasatinib for 24 hours.  Note migration in the HaCaT-Fyn and HaCaT-
Ras cells was significantly inhibited by 0.1 μM Dasatinib treatment (*p<0.001) 
and 1.0 μM Dasatinib treatment (#p<0.001).  Data shown is a representative 
experiment that was performed in duplicate. 
 
 
 
  
 
 
Untreated 
0.1 μM Dasatinib 
 1 μM Dasatinib 
 
* 
* 
* 
* 
# 
# 
# 
# 
 
124 
 
 
 
5.3 Dasatinib Treatment and Fyn Inhibition Induces the Formation of F-actin 
 
 
 
Dasatinib treatment upregulated cell-cell adhesion and this change appeared to be stable 
for as long as the cells were cultured in the drug (Figure 41).  Keratinocytes have two 
main junctions responsible for maintaining cell-cell adhesion, the desmosome and the 
adherens junction.  Because Dasatinib did not restore pan-cytokeratin expression (Figure 
35), we concluded that the desmosome was most likely not mediating the Dasatinib-
induced change in cell-cell adhesion.  To assess whether changes in cell-cell adhesion 
following Dasatinib exposure were occurring through the actin-based adherens junction, 
we stained for polymerized F-actin using Rhodamine-phalloidin.  Following treatment 
with 1 μM Dasatinib, the HaCaT-Ras cells rapidly increased levels of F-actin from 5 
minutes to 1 hour, and F-actin levels remained elevated approximately 10-fold at 24 
hours (Figure 36).  We also biochemically fractionated free G-actin and polymerized F-
actin and quantified them by Western blotting.  Dasatinib increased the F-actin/G-actin 
ratio in HaCaT-Ras cells, while total actin remained unchanged, and Dasatinib did not 
alter the F-actin/G-actin ratio in HaCaT cells (Figure 37).  Because Dasatinib can inhibit 
multiple kinases, the induction of F-actin we observed may not be due solely to inhibition 
of Fyn.  Therefore we used Fyn siRNA to reduce Fyn levels and test whether direct Fyn 
inhibition is sufficient to induce F-actin formation.  Fyn knockdown significantly 
increased F-actin levels in HaCaT-Ras cells (p<0.001) (Figure 38) and MDA-MB-231 
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cells (p<0.01) (Figure 43) (Yadav and Denning, 2011).  Thus, inhibition of Fyn is 
sufficient to increase F-actin levels.   
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Figure 35: Dasatinib Treatment Does Not Restore Cytokeratin Expression in 
HaCaT-Fyn or HaCaT-Ras Cells 
 
Following treatment with 1 μM Dasatinib for 24 hours, protein levels of pan-
cytokeratin were measured using Western blot techniques on lysates from HaCaT, 
HaCaT-Fyn and HaCaT-Ras cells.  β-actin was used as a loading control.  Data 
shown is a representative experiment that was performed in duplicate.   
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Figure 36: Dasatinib Treatment Increases F-actin Levels in HaCaT-Ras Cells 
 
HaCaT-Ras cells were treated with 1.0 µM Dasatinib for the indicated times and 
then stained w ith Rhodamine-phalloidin and DAPI.  The insert in the upper right 
of each picture shows higher magnification.  Quantitation of Rhodamine-
phalloidin staining normalized to the number of DAPI nuclei is shown in the 
graph.  Data shown is a representative experiment that was performed in 
triplicate. 
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Figure 37: Dasatinib Treatment Increases the F-actin Fraction in HaCaT-
Ras Cells 
 
HaCaT and HaCaT-Ras cells were treated with or without 1.0 µM Dasatinib for 
30 minutes and fractionated into soluble (G-actin) and insoluble (F-actin) 
fractions.  Shown is a Western blot for F-actin, G-actin and total actin.  Data 
shown is a representative experiment that was performed in duplicate.    
 
 
 
 
 
 
 
 
 
 
 
 
 
129 
 
 
 
 
 
 
 
 
Figure 38: Fyn Knockdown Increases F-actin in HaCaT-Ras Cells 
 
HaCaT-Ras cells were transfected with control or Fyn siRNA and stained with 
Rhodamine-phalloidin and DAPI after 72 hours.  Quantitation of Rhodamine-
phalloidin staining normalized to the number of DAPI nuclei indicates F-actin is 
significantly increased following Fyn knockdown (*p<0.001).  Data shown is a 
representative experiment that was performed in triplicate. 
  
* 
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5.4 Dasatinib Treatment Induces the Formation of Stable Adherens Junctions 
 
 
 
To determine if increased F-actin colocalized with the cytoskeletal linker catenins found 
in the adherens junction, we performed immunofluorescent staining for F-actin and α-
catenin, β-catenin or p120catenin (Figure 39).  Prior to Dasatinib exposure, α-catenin, β-
catenin and p120catenin were diffusely localized in HaCaT-Ras cells (Figure 40).  
However, treatment with 1 μM Dasatinib for one hour resulted in translocation of these 
catenins to the plasma membrane, where α-catenin, β-catenin and p120catenin 
colocalized with F-actin (Figures 39 & 40, data not shown for α-catenin and β-catenin).  
These results indicate that Dasatinib treatment was increasing cell-cell adhesion by 
inducing the formation of stable adherens junctions. 
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Figure 39: Dasatinib Treatment Results in Localization of Adherens Junction 
Components to the Cell Membrane 
 
HaCaT-Ras cells remained untreated or were treated with 1 μM Dasatinib for 30 
minutes.  Shown is immunofluorescent staining for three components of the 
adherens junction, α-catenin, β-catenin and p120catenin.  Data shown is a 
representative experiment that was performed in triplicate. 
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Figure 40: Dasatinib Treatment Results in the Formation of Stable Adherens 
Junctions in HaCaT-Ras Cells 
 
Staining for p120catenin and F-actin (stained with Rhodamine-phalloidin) in 
HaCaT-Ras cells following 30 minutes of 1 μM Dasatinib exposure is shown.  
Note that Dasatinib induces colocalization between p120catenin and the cortical 
F-actin cytoskeleton.   Data shown is a representative experiment that was 
performed in triplicate. 
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5.5 Fyn Inhibition Upregulates F-actin By Release of Rho Inhibition 
 
 
 
The Rho family of GTPases regulates the stability of the actin cytoskeleton, with Rho 
activity increasing levels of actin stress fibers (Menke and Giehl, 2012, Kaibuchi, Kuroda 
and Amano, 1999).  Since Dasatinib rapidly induced F-actin levels in HaCaT-Ras cells, 
we tested if Dasatinib-induced F-actin was dependent on Rho signaling.  Pretreatment of 
HaCaT-Ras cells with 20 μM Y27632, an inhibitor of the Rho effector ROCK (also 
known as Rho-associated protein kinase), blocked Dasatinib’s ability to upregulate F-
actin (Figure 41).  Similarly, pretreatment of HaCaT-Fyn cells and MDA-MB-231 cells 
with 20 μM Y27632 also blocked Dasatinib’s induction of F-actin (Figures 42 & 43).  
Treatment of HaCaT cells with Dasatinib did not increase F-actin levels and Y27632 
exposure only slightly decreased levels of F-actin (Figure 44).  These results suggest that 
Fyn activity inhibits Rho function and Dasatinib releases this inhibition, inducing 
upregulation of the F-actin cytoskeleton.   
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Figure 41: Co-Treatment with a ROCK Inhibitor Blocks Dasatinib-Induced F-actin 
in HaCaT-Ras Cells 
 
HaCaT-Ras cells were pre-treated with 20 μM Y27632, an inhibitor of ROCK, for 20 minutes, followed by 
cotreatment with 1 μM Dasatinib for 30 minutes.  Staining for F-actin using Rhodamine-phalloidin 
indicated that Y27632 significantly inhibited (*p<0.001) the Dasati nib-mediated increase in F-actin.  
Quantitation of Rhodamine-phalloidin staining normalized to the number of DAPI nuclei is shown below.  
Data shown is a representative experiment that was performed in triplicate. 
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Figure 42: Co-Treatment with a ROCK Inhibitor Blocks Dasatinib-Induced 
F-actin in HaCaT-Fyn Cells 
 
HaCaT-Fyn cells were pre-treated with 20 μM Y27632 for 20 minutes followed by cotreatment 
with 1 μM Dasatinib for 30 minutes.  Staining for F-actin using Rhodamine-phalloidin indicated 
that Y27632 cotreatment significantly inhibited (*p<0.001) the Dasatinib-mediated increase in F-
actin.  Quantitation of Rhodamine-phalloidin staining normalized to the number of DAPI nuc lei is 
shown below.  Data shown is a representative experiment that was performed in triplica te.  
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Figure 43: Co-Treatment with a ROCK Inhibitor Blocks Dasatinib-Induced 
F-actin in MDA-MB-231 Cells 
 
MDA-MB-231 cells were pre-treated with 20μM Y27632, an inhibit or of the Rho effector protein 
ROCK, for twenty minutes, followed by cotreatment with 1μM Dasatinib for 30 minutes.  Staining 
for F-actin using Rhodamine-phalloidin indicated that Y27632 cotreatment significantly inhibited 
(*p<0.001) the Dasatinib-mediated increase in F-actin.  Quantitation of Rhodamine-phalloidin 
staining normalized to the number of DAPI nuclei is shown below.  Data shown is a representative 
experiment that was performed in duplicate.  
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Figure 44: Dasatinib Treatment Does Not Alter F-actin in HaCaT Cells and 
Y27632 Only Slightly Decreases F-actin Levels 
 
HaCaT cells were pre-treated with 20μM Y27632, an inhibitor of the Rho effector protein ROCK, 
for twenty minutes, followed by cotreatment with 1μM Dasatinib for 30 minutes.  Staining for F-
actin using Rhodamine-phalloidin indicated that neither Dasatinib nor Y27632 treatment 
significantly reduced levels of F-actin.  Quantitation of Rhodamine-phalloidin staining normalized 
to the number of DAPI nuclei is sh own below.  Data shown is a representative experiment that 
was performed in duplicate.  
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5.6 Increased F-actin Polymerization Drives the Increase in Cell-Cell Adhesion 
 
In our previous experiments blocking Dasatinib’s effects on F-actin through ROCK 
inhibition, we observed the cells no longer formed aggregates in the cell culture plate 
(Figures 41 & 42), suggesting that the increase in cell-cell adhesion required or was 
driven by the increase in F-actin.  To explore this possibility, we first determined that 
Y27632 pre-treatment prevented an increase in cell-cell adhesion following Dasatinib 
treatment in HaCaT-Ras cells by performing a cell-cell adhesion assay (Figure 45).  We 
then pretreated HaCaT-Ras cells with 0.1 μg/mL Cytochalasin D for 30 minutes to 
prevent actin polymerization and treated the cells with Dasatinib.  Pretreatment with 
Cytochalasin D blocked the Dasatinib-induced increase in cell-cell adhesion in HaCaT-
Ras cells (Figure 45).  Furthermore, disruption of cell-cell adhesion by culturing cells in 
low Ca+2 media did not prevent Dasatinib-induced F-actin levels (Figure 46).  Together, 
these results indicate that actin polymerization is necessary to allow the increase in cell-
cell adhesion induced by Dasatinib in HaCaT-Ras cells.   
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Figure 45: Blocking Actin Polymerization or ROCK Activity Prevents the 
Dasatinib-Induced Increase in Cell-Cell Adhesion 
 
HaCaT-Ras cells were pretreated with either 0.1 μg/mL Cytochalasin D or 20 μM 
Y27632 for 20 minutes followed by 30 minutes of 1 μM Dasatinib exposure.  
Cell-cell adhesion was assayed using the dispase assay.  Dasatinib-mediated cell-
cell adhesion in HaCaT-Ras cells was significantly inhibited by both Cytochalasin 
D (*p<0.001) and Y27632 (#p<0.001).  Data shown is a representative experiment 
that was performed in duplicate. 
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Figure 46: Culture in Low Ca+2 Media Does Not Prevent Dasatinib-Induced 
F-actin Upregulation 
 
HaCaT-Ras cells were treated with 1 μM Dasatinib for 30 minutes in either high Ca2+ media 
(DMEM) or low Ca2+ media (Media 154) and stained with Rhodamine-phalloidin.  Quantitation of 
Rhodamine-phalloidin staining normalized to the number of DAPI nuclei is shown below.  Data 
shown is a representative experiment that was performed in triplicate. 
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Figure 47: Culture in Low Ca+2 Media Prevents Dasatinib-Induced Cell-Cell 
Adhesion 
 
HaCaT-Ras cells were treated with 1 μM Dasatinib for 30 minutes in either high 
Ca2+ or low Ca2+ media and assayed for cell-cell adhesion.  Low Ca2+ media 
significantly inhibited Dasatinib-induced cell-cell adhesion (*p<0.001).  Data 
shown is a representative experiment that was performed in duplicate. 
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5.7 Summary 
 
Following Dasatinib treatment the HaCaT-Ras and HaCaT-Fyn cells underwent a marked 
change in appearance (Figure 20), but this change was not accompanied by a reduction in 
cell viability or increase in apoptosis compared to the parental HaCaT cells (Figures 24 & 
28).  However, Fyn inhibition using Dasatinib and siRNA increased cell-cell adhesion in 
HaCaT-Ras, HaCaT-Fyn and MDA-MB-231 cells, all of which have upregulated Fyn 
expression (Figures 31, 32 & 33).  When cells acquire the ability to migrate they must 
downregulate their adhesion structures and reduce the stability of the actin cytoskeleton.  
Increased Fyn activity is sufficient to increase the migratory capacity of HaCaT cells, and 
Dasatinib treatment, in turn, is sufficient to inhibit this migration (Figure 34) (Yadav and 
Denning, 2011).  Following Dasatinib exposure, the cells expressing high levels of Fyn 
upregulated the levels of polymerized F-actin, and this F-actin co-localized with catenin 
members of the adherens junction, suggesting increased stable cell-cell adhesion through 
the adherens junction (Figures 36, 38 & 40).  Furthermore, inhibition of the Rho pathway 
prevented this increase in F-actin following Dasatinib treatment (Figure 41).  These 
results suggest that increased Fyn is inhibiting Rho to decrease levels of F-actin, 
decreasing the stability of cell-cell adhesions and increasing the migratory capacity of the 
cells.  Dasatinib treatment inhibits Fyn to restore Rho activity, increasing levels of F-
actin to drive the formation of stable adherens junctions.   
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CHAPTER VI 
TARGETING FYN IN A UV MODEL 
OF SKIN CARCINOGENESIS 
 
 
6.1 Abstract 
 
cSCC is the second most common type of skin cancer with over 700,000 diagnoses made 
every year in the United States of America alone, and this number is only growing 
(Weinstock, 1989).  Despite the high rate of diagnosis, most cSCCs are successfully 
treated with surgical excision and only 1% of cases result in mortality (LeBoeuf and 
Schmults, 2011, Newman, 1991).  However, patients diagnosed with cSCC are at higher 
lifelong risk for secondary tumors and these recurrences are usually more malignant 
(Veness et al, 2003).  There are currently no treatment therapies that target the molecular 
mechanism of cSCC tumorigenesis.  By developing specific therapeutic protocols, we 
may reduce some of the physical deformity created by current treatment protocols, reduce 
tumor recurrence and potentially develop an intervention strategy, greatly reducing the 
economic strain created by current therapies (Clayman et al, 2005).   
 
The introduction of active Fyn in the epidermis of a murine model results in the 
formation of actinic keratoses and SCCs (Zhao et al, 2009).  We used an in vivo model of 
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UV-induced skin tumors in SKH1 hairless mice and followed each UV exposure with 10 
nmole or 100 nmole topical Dasatinib treatment (Figure 48).  Following 23 weeks of UV 
exposure, the mice treated with Dasatinib had a significant reduction in total tumor 
burden, suggesting SFK inhibition may be an effective method of tumor prevention 
(Figure 49). 
 
6.2 Treatment with Dasatinib Reduces Total Tumor Burden in a UV-Model of Skin 
Carcinogenesis 
 
The results thus far demonstrate that Ras-mediated Fyn upregulation results in decreased 
cell-cell adhesion and an increased migratory potential, two cancer-associated 
phenotypes.  The identification of EMT markers in cSCC significantly increases the risk 
of cancer associated mortality (Clayman et al, 2005).  Furthermore, Fyn is over-expressed 
in human cSCC and is oncogenic in mouse epidermis (Zhao et al, 2009).  To test if 
inhibiting Fyn might mitigate UV-induced skin carcinogenesis, we exposed three groups 
of SKH1 hairless mice (12 mice/group) to increasing doses of UVB (30 mJ/cm² - 150 
mJ/cm²) three times a week for 23 weeks.  Immediately following each UVB exposure 
we administered a topical dose of acetone, 10 nmole Dasatinib in acetone or 100 nmole 
Dasatinib in acetone to each group (Figure 48).  Dasatinib was applied after UVB 
exposure to avoid any sunscreen effects.  After 23 weeks of UV exposure, the mice were 
allowed to recover for a week before tumor analysis.  Both Dasatinib treatments 
significantly reduced the total tumor burden per mouse (p<0.05) (Figure 49).  However, 
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the average size of each tumor did not change significantly (Figure 50).  Additionally, 
there was not difference in the mouse weights between tumor groups, indicating 
Dasatinib treatment did not decrease the viability of the mice (Figure 54).  These results 
suggest that the tumor burden was primarily lessened by a decrease in the total number of 
tumors, although this difference was not significant (Figure 51).  It is possible that the 
Dasatinib-treated mice developed fewer total tumors due to higher levels of apoptosis in 
the UV-damaged cells.  Previous studies of Dasatinib-induced apoptosis in HaCaT cells 
indicated that Dasatinib additively increased levels of apoptosis following UVB exposure 
(Figure 30).  The distribution of benign tumors, atypical benign tumors and squamous 
cell carcinomas that arose in the control or Dasatinib treated groups was similar (Figure 
52b), indicating that there was not a significant difference in tumor histopathology 
between groups (Figure 52a).  Staining for the differentiation marker Keratin 1 exposed a 
significant difference in the differentiation status of tumors between the groups, with 
more poorly differentiated tumors in the Dasatinib-treated groups (Figure 53).   
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Figure 48: In Vivo Model of UV-Induced Skin Carcinogenesis with Dasatinib 
treatment 
 
Schematic describing UV exposure and Dasatinib treatment in the SKH1 mouse 
model.  Three groups of mice were exposed to increasing doses of UVB (30 
mJ/cm² - 150 mJ/cm²) three times a week for 23 weeks, followed by topical 
treatment with acetone, 10 nmole Dasatinib in acetone or 100 nmole Dasatinib in 
acetone.  Mice were allowed to recover for 1 week before tumor analysis.  Figure 
courtesy of Dr. Mitchell F. Denning. 
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Figure 49: Dasatinib Treatment Following UV Exposure Reduces Total 
Tumor Burden 
 
Three groups of twelve SKH1 mice were exposed to increasing doses of UVB (30 
mJ/cm² - 150 mJ/cm²) 3x a week for 23 weeks.  Each UVB exposure was 
immediately followed by treatment with acetone alone (control), 10 nmole 
Dasatinib or 100 nmole Dasatinib, and tumor size and number was quantified 
after 24 weeks.  Total tumor burden was significantly reduced by both the 10 
nmole treatment (*p<0.05) and 100 nmole treatment (#p<0.01). 
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Figure 50: Dasatinib Treatment Following UV Exposure Did Not Decrease 
Tumor Size 
 
Average tumor size per mouse in each treatment group is shown. 
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Figure 51: Dasatinib Treatment Following UV Exposure Reduced Tumor 
Number 
 
Average number of tumors per mouse in each treatment group is shown. 
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Figure 52: Dasatinib Treatment Did Not Alter Distribution of Tumor Types 
Following UV Exposure 
 
A. One week after the end of UV exposure tumors were taken for histopathology.  
Shown are representative hematoxylin and eosin (H&E) stained sections of UV-
irradiated dorsal epidermis (IF Ventral), a benign papilloma (1B), a progressing 
papilloma (2K) and a squamous cell carcinoma (3L). 
B. Histology of UV-induced SKH1 mouse tumors is summarized for each 
treatment group based on analysis of H&E stained tumor sections.   
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Figure 53: Dasatinib Treatment Resulted in Tumors with Decreased 
Differentiation Status 
 
A. Tumors were stained for Keratin 1 expression.  Shown are representative 
immunofluorescent stained sections of UV-irradiated dorsal epidermis (IF 
Ventral), a benign papilloma (1B), a progressing papilloma (2K) and a squamous 
cell carcinoma (3L) with corresponding analysis of K1 expression. 
B. Staining of UV-induced SKH1 mouse tumors is summarized for each treatment 
group based on analysis of Keratin 1 sta ined tumor sections.  Dasatinib treatment 
resulted in significantly more tumors with loss of K1 staining (p<0.005).  
Statistical analysis was performed using Fisher’s Exact Test.     
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Figure 54: Dasatinib Treatment Did Not Alter Mouse Weight 
 
Mice were weighed during the duration of the experiment on the dates indicated.  
Weights are shown in grams. UVB exposure began at week 1 and ended at week 
23. 
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6.3 Summary 
 
UVB exposure is the most common carcinogen driving the formation of cSCCs (Alam 
and Ratner, 2001).  We exposed 36 SKH1 hairless mice to increasing doses of UVB and 
followed each exposure with two different cutaneous Dasatinib doses (10 and 100 
nmole).  After 23 weeks all of the mice had developed skin tumors, but both Dasatinib 
treatments resulted in a significant reduction in total tumor burden (Figure 49).  The 
tumor sizes did not vary between treatment groups, but the 10 nmole and 100 nmole 
treatments both caused a reduction in the number of tumors that formed (Figure 50 & 51).  
There was also no difference in the distribution of benign and malignant tumors between 
groups (Figure 52).  However, there was a significant increase in poorly differentiated 
tumors in the Dasatinib treated mice (Figure 53).  Although Dasatinib treatment did 
reduce total tumor burden, further studies with longer time points are required to 
investigate how SFK inhibition alters the malignant potential of the tumors that do form.   
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CHAPTER VII 
DISCUSSION 
 
 
7.1 FYN Expression May Be Regulated by the Transcription Factor Lef-1 
 
Fyn over-expression has been detected in many different human malignancies, including 
cSCC, glioblastoma multiforme, head and neck squamous cell carcinoma, melanoma, 
pancreatic and prostate cancer (Zhao et al, 2009, Saito et al, 2010, Ban et al, 2008, Lu et 
al, 2009, Posadas et al, 2009, Talantov et al, 2005).  However, the signaling mechanism 
governing FYN transcriptional regulation has only been described in CML, where BCR-
ABL drives ROS production to activate the transcription factors Egr and Sp1, increasing 
FYN expression (Gao et al, 2009).  A previous graduate student, Vipin Yadav, found that 
the introduction of active H-Ras(G12V) to the HaCaT keratinocyte cell line resulted in 
upregulation of Fyn expression through a PI3K/Akt dependent mechanism (Yadav and 
Denning, 2011).  Using RT-qPCR techniques I found that FYN was selectively 
upregulated over 200-fold (Figure 6).  However, depletion of ROS in the cell culture 
media did not decrease activity at the FYN promoter, suggesting FYN expression was 
being regulated by a different mechanism than that identified in CML (Figure 8). 
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The gene encoding FYN is located on chromosome 6q21 and spans approximately 
213,120 base pairs.  14 exons spliced from FYN’s mRNA transcript are translated to a 
protein that is 537 amino acids long.  Using luciferase reporter constructs, we identified 
the region between -100 and -50 bases upstream of the transcription start site as necessary 
for FYN upregulation in HaCaT-Ras cells (Figure 9).  Mutation of the GA sequence 
located -74 bases upstream of the transcription start site abolished FYN expression, 
underlining the importance of this region in FYN regulation (Figure 10).  It is worth 
nothing that this site is different than that identified by Gao et al. in their paper describing 
ROS-mediated FYN transcriptional regulation (Figure 55) (Gao et al, 2009).   
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Figure 55: Diagram of Transcription Factor Binding to the FYN Promoter 
 
Transcription factor binding sites in the FYN promoter identified in our work and 
work performed by the Chandra lab are diagramed in the figure above.  Luciferase 
reporter analysis and EMSA identified Lef-1 (green) as the transcription factor 
binding -74 base pairs upstream of the transcription start site and mediating FYN 
upregulation in Ras-transformed keratinocytes.  Luciferase reporter analysis and 
ChIP identified Sp1 and Egr1 (orange) as the transcription factors binding -147-
138, -41-32 and -128-120 base pairs (respectively) upstream of the transcription 
start site and mediating FYN upregulation in BCR-ABL-transformed leukemic 
cells.    
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Vipin Yadav found that the PI3K/Akt pathway was mediating Fyn upregulation in Ras-
transformed HaCaT cells (Yadav and Denning, 2011).  Akt plays many important roles in 
the cell, inhibiting apoptosis and regulating cell proliferation, autophagy and metabolism.  
Akt activity has been associated with dozens of transcription factors, and four of these 
proteins were also predicted to bind near the site necessary for FYN upregulation in our 
system, -74 base pairs upstream of the transcription start site.  These transcription factors 
were GATA-1, GATA-2, GATA-3 and Lef-1 (Zhao et al, 2006, Menghini et al, 2005, 
Song, Hollstein and Xu, 2007, Huang et al, 2012).  Initial EMSA analysis of transcription 
factor binding suggested Lef-1 may be binding to the site of interest in HaCaT-Ras cells 
(Figure 16).  However, knocking down Lef-1 in HaCaT-Ras cells did not decrease FYN 
mRNA levels (Figure 17).  Lef-1 is a member of the TCF family of transcription factors, 
and these proteins are capable of functionally substituting for each other in vivo (Staal 
and Clevers, 2000).  Therefore we also knocked down an essential binding partner for 
Lef-1/TCF transcriptional regulation, β-catenin.  Knockdown of β-catenin also did not 
decrease FYN mRNA levels (Figure 18).  Together, these results contradict our EMSA 
findings that suggest Lef-1 was mediating FYN upregulation in HaCaT-Ras cells.  This 
discrepancy could be the result of many different factors.  Our knock-down may not have 
been complete enough to reduced Lef-1 or β-catenin activity below what is necessary to 
see loss of FYN transcription, or other closely related proteins such as TCF7 may have 
replaced Lef-1 in regulating FYN over-expression in the HaCaT-Ras cells.  Alternatively, 
our largest reporter plasmid contained 2,000 base pairs of the FYN promoter.  Although 
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this region surely contains some regulatory elements regarding FYN transcription, it may 
not have encompassed enhancers or other regions of importance further upstream or 
downstream of this segment that play important roles in FYN regulation in vivo.  
Additionally, our in vitro EMSA results may have identified a potential interaction 
between Lef-1 and the FYN promoter that is not occurring in vivo in our HaCaT-Ras cells 
due to signaling mechanisms that were not detected following the introduction of reporter 
plasmids.   
 
7.2 Increased Fyn Activity is Sufficient to Induce EMT in Keratinocytes   
 
Fyn has previously been described as an initiator of EMT (Saito et al, 2010, Lewin et al, 
2010).  Increased Fyn activity has been implicated in the increased migratory potential of 
melanoma and prostate cancer cells, as well as increased metastasis in oral and pancreatic 
tumors (Saito et al, 2010, Jensen et al, 2011, Huang et al, 2003, Chen et al, 2009b, Li et 
al, 2003).  Additionally, studies have uncovered a role for Fyn in the down-regulation of 
E-cadherin in A549 lung cancer cells, and inhibition of Src in Ras-transformed HaCaT 
cells stabilized E-cadherin at the cell membrane, implicating SFKs like Fyn as negative 
regulators of E-cadherin stability (Kim et al, 2011, Alt-Holland et al, 2008).  Fyn is also 
capable of phosphorylating β-catenin at two sites that break the connection between β-
catenin and both E-cadherin and the actin cytoskeleton.  These phosphorylation events 
free β-catenin from the cell membrane, allowing its translocation to the nucleus and 
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upregulation of TCF/LEF target genes (Piedra et al, 2003, Castano et al, 2007).  In 
HaCaT cells, increased Fyn expression resulted in the downregulation of E-cadherin and 
cytokeratin, upregulation of vimentin and the transition from a cobblestone, epithelial 
morphology to a small, stellate, mesenchymal morphology, all of which are markers of 
EMT (Figures 19 & 20).  We used RT-qPCR to analyze the mRNA levels of three 
transcription factors considered master regulators of EMT: Slug, Snail and Twist.  Both 
the HaCaT-Fyn and HaCaT-Ras cells had upregulated expression levels of Twist over 40-
fold, suggesting this was the mechanism driving EMT in these cells (Figure 23).  
Although EMT is a normal process in embryogenesis and wound healing, the acquisition 
of a mesenchymal, migratory phenotype is considered an important step in the 
progression of epithelial malignancies (Radisky, 2005, Kalluri and Weinberg, 2009b).  In 
cSCC, the identification of invasion or a migratory capacity decreases the predicted three 
year disease free survival rate by thirty percent (Clayman et al, 2005).  Therefore, the 
identification of Fyn as a potential driver of EMT in cSCC is an important contribution to 
our understanding of the development of particularly malignant skin tumors.   
 
Due to Fyn’s ability to induce EMT in keratinocytes, we chose to block Fyn activity 
using Dasatinib, an inhibitor of SFKs, BCR-ABL and other kinases (Aguilera and 
Tsimberidou, 2009).  Although Dasatinib treatment did not reverse expression of the 
markers of EMT, it did inhibit cell migration and promote cell-cell adhesion, two 
important features of the EMT phenotype (Figures 22, 31 & 34).  RT-qPCR analysis of 
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expression levels of Slug, Snail and Twist following 24 hours in 1 μM Dasatinib showed 
no reduction of expression to levels comparable to those in the parental HaCaT cells 
(Figure 23).  Therefore, it is possible that once the cells had undergone EMT, positive 
feedback mechanisms were activated to drive and maintain the mesenchymal phenotype, 
and inhibition of Fyn was no longer sufficient to reverse EMT (Saunders and McClay, 
2014).     
 
7.3 Dasatinib Treatment Decreases Cell Viability to a Similar Extent in Parental 
and Transformed Keratinocytes 
 
Reduced Fyn signaling, either directly or using the SFK inhibitor Dasatinib, results in 
decreased cellular proliferation in several cell systems, including osteoclasts and T-cells, 
among others (Singh et al, 2012, Kim et al, 2010, Schade et al, 2008, Ninio-Many et al, 
2013).  Other groups have also shown that Fyn activity inhibits apoptosis and promotes 
cell survival, either by upregulating Sam68 and HnRNPA2B1 activity or by preventing 
PIKE-A cleavage to increase Akt activity and prevent cell death (Chen et al, 2011, Tang, 
Feng and Ye, 2007).  Following 24 hours in 0.1 μM or 1 μM Dasatinib, we saw a similar 
decrease in cell viability between the parental HaCaT and HaCaT-Ras cells (Figure 24).  
We could not detect a decrease in proliferation using DNA quantitation or radioactive 
thymidine incorporation upon Dasatinib exposure (Figures 25 & 26).  Finally, treatment 
with Dasatinib induced apoptosis in both cell lines to a similar extent and did not induce 
autophagy (Figure 28 & 29).  From these results it appears likely that upregulated Fyn 
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activity is not increasing proliferation or resistance to apoptosis in HaCaT-Ras cells.  
Instead of acting as a survival factor, our results indicate that increased Fyn signaling is 
decreasing the strength of cell-cell adhesions and increasing cell motility, promoting the 
transition to a mesenchymal phenotype. 
 
7.4 Dasatinib Treatment Results in Increased Cell-Cell Adhesion 
 
During KC differentiation, Fyn is involved in the formation of adherens junctions, 
recruiting junctional components and inducing signaling pathways that control the 
differentiation program (Calautti et al, 1995, Tu et al, 2008, Cabodi et al, 2000).  
However, in KC transformation and oncogenesis, Fyn activity has been implicated in the 
dissolution of cell-cell adhesion structures and an increased migratory phenotype (Owens 
et al, 2000, Roura et al, 1999).  Fyn activity is also associated with both the formation 
and dissolution of focal adhesions, and to a lesser extent hemidesmosomes and 
desmosomes (Rengifo-Cam et al, 2004, Zeng et al, 2003, Sharma and Mayer, 2008, Peng 
and Guan, 2011, Schober et al, 2007, Mariotti et al, 2001, Spinardi et al, 2004, Gagnoux-
Palacios et al, 2003).  Treatment with 0.1 µM or 1 µM Dasatinib did not increase cell-cell 
adhesion in the parental HaCaT cells, most likely because these cells already had a robust 
cortical F-actin cytoskeleton and strong cell-cell adhesion (Figures 31 & 44).  However, 
in keratinocytes stably expressing active Fyn (HaCaT-Fyn cells) or Ras (HaCaT-Ras 
cells), Dasatinib exposure rapidly increased cell-cell adhesion over 6-fold (Figure 31).  
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Fyn knockdown using siRNA had a similar result, demonstrating that Fyn inhibition is 
sufficient to induce an increase in cell-cell adhesion (Figure 32).  These findings apply to 
cell types other than keratinocytes, as Fyn knockdown in MDA-MB-231 breast cancer 
epithelial cells also increased cell-cell adhesion (Figure 33).  Our results support a 
previously established role for Fyn in the turnover of adherens junctions through 
phosphorylation of p120catenin and β-catenin, ultimately causing dissociation of the 
adherens junction complex from the actin cytoskeleton and loss of cell-cell adhesion 
(Calautti et al, 1998, Piedra et al, 2003, Lilien and Balsamo, 2005, Castano et al, 2007).   
 
In conjunction with an increase in cell-cell adhesion following Dasatinib treatment in 
HaCaT-Ras and HaCaT-Fyn cells (Figure 31 & 32), we also observed an interesting 
change in the cell’s ability to remain adhered to the culture plate.  In cultures with high 
cell density we observed Dasatinib treatment induced cell-cell adhesion, and these tight 
clumps of cells were easily dislodged from the plastic, resulting in floating rafts of cells 
that remained adhered to each other but not to the matrix.  We have generated two 
hypotheses that may account for this change in cell-cell adhesion.  First, although the 
strength and number of cell-matrix adhesions may not been altered, the increase in cell-
cell adhesion may reduce the cell’s ability to remain adhered following the physical 
dislodgement induced by the media moving around in the plate.  Second, a great deal of 
cross-talk occurs between the cell-cell adhesion complexes and cell-matrix complexes.  
Increased Fyn activity has been shown to shift the actin cytoskeleton, an important 
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stabilizing component of adhesion complexes, away from adherens junctions and toward 
focal adhesions (Rengifo-Cam et al, 2004).  Therefore, following Fyn inhibition, 
increased stability at the adherens junction may signal for decreased stability at the focal 
adhesion, resulting in decreased adherence to the matrix and an increase in cell 
detachment, thus resulting in the floating rafts of cells that we observed.  Although we 
have not studied Dasatinib’s ability to alter cell-matrix adhesion in HaCaT-Ras and 
HaCaT-Fyn cells, it remains an interesting avenue of research that may shed additional 
light on the role of Fyn as a target in cSCCs.    
 
It is important to note that Dasatinib is not a specific inhibitor of Fyn; instead it decreases 
the activity of all SFKs, BCR-ABL and other tyrosine kinases (Figure 21) (Aguilera and 
Tsimberidou, 2009, Lombardo et al, 2004).  However, our Dasatinib treatment results can 
be primarily attributed to inhibition of Fyn activity, as it is the only SFK differentially 
regulated between our parental HaCaT and HaCaT-Ras cells, and results similar to those 
seen with Dasatinib treatment were observed with Fyn knockdown using siRNA.  
Additionally, the introduction of active Fyn was sufficient to drive EMT in HaCaT cells, 
and Dasatinib treatment of these HaCaT-Fyn cells promoted cell-cell adhesion and 
increased F-actin levels.  Dasatinib also requires a much lower in vitro IC50 to inhibit 
SFKs (0.5 nM) than any of its other targets (Aguilera and Tsimberidou, 2009, Lombardo 
et al, 2004).  This IC50 was determined in a test tube, where lower concentrations of the 
inhibitor are required to out-compete ATP from the SFK binding site.  In cells, higher 
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concentrations of ATP competitive kinase inhibitors are required due to the higher 
intracellular levels of ATP (1-10 mM).  The concentrations of Dasatinib used in our 
experiments (0.1 and 1 µM) are comparable to those used in other studies to treat cells in 
culture (Li et al, 2010, Buettner et al, 2008).   
 
7.5 Dasatinib Treatment Results in Increased Polymerized F-actin, Driving the 
Formation of Adherens Junctions  
 
 
EMT is commonly associated with an increase in the dynamic nature of the actin 
cytoskeleton, resulting in loss of cell-cell adhesion, cell detachment and migration 
(Radisky, 2005, Kalluri and Weinberg, 2009b).  Fyn activity has been implicated in the 
dissolution of cell-cell adhesions, phosphorylating β-catenin and p120catenin to induce 
rearrangement of the actin cytoskeleton away from adherens junctions and toward focal 
contacts, a premature form of focal adhesions (Rengifo-Cam et al, 2004).  Following 
Dasatinib exposure in the HaCaT-Ras cells, we could not detect an increase in the 
expression of the cytokeratins either by Western blot or immunofluorescent staining 
(Figure 35, data not shown), making the formation of desmosomes an unlikely 
mechanism of Dasatinib-induced cell-cell adhesion.  In contrast, levels of polymerized F-
actin increased as early as five minutes after Dasatinib exposure, continued to increase 
for 6 hours and remained elevated for over 24 hours (Figure 36).  This increase in F-actin 
was also seen in HaCaT-Ras cells following Fyn knockdown using siRNA, indicating 
that Fyn inhibition is sufficient to cause these changes (Figure 38).  Furthermore, the F-
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actin induced by Dasatinib formed a cortical cytoskeleton that colocalized with the 
adherens junction proteins α-catenin, β-catenin and p120catenin, suggesting the 
formation of stable adherens junctions (Figure 40).  It is worth noting that the parental 
HaCaT cells had higher levels of F-actin prior to treatment, and Dasatinib exposure did 
not alter the levels of polymerized actin (Figure 44).  This suggests that Dasatinib’s 
effects are not universal on all cell types.  Instead, Dasatinib treatment acts to upregulate 
the F-actin cytoskeleton and cell-cell adhesion in cancer cells that have undergone some 
degree of EMT. 
 
The ability of the Rho family of proteins to regulate actin stability has been well 
established (Owens et al, 2000, Grosheva et al, 2001, Cozzolino et al, 2003, Menke and 
Giehl, 2012, Wildenberg et al, 2006).  Rho acts to increase the formation of actin stress 
fibers, while its family member Rac decreases the stability of cell-cell adhesions and 
indirectly decreases the stability of the actin cytoskeleton (Lamouille, Xu and Derynck, 
2014, Whale et al, 2011).  Previous work in oligodendrocytes has uncovered a 
relationship between Fyn activity and actin stability, where Fyn phosphorylates 
p190RhoGAP to inhibit Rho, ultimately causing disassembly of the actin cytoskeleton 
(Wolf et al, 2001, Liang, Draghi and Resh, 2004).  In HaCaT-Ras cells, following 
inhibition of the downstream Rho effector protein ROCK, Dasatinib exposure no longer 
upregulated levels of F-actin (Figure 41).  These results suggest that, in keratinocytes, 
Fyn inhibits Rho activity, and Dasatinib treatment releases this inhibition to activate Rho, 
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ultimately promoting actin cytoskeletal stability.  This dependence on ROCK for 
Dasatinib-induced F-actin was also seen in HaCaT-Fyn and MDA-MB-231 cells (Figures 
42 & 43).   
 
The existing body of literature concerning Fyn’s role in cell-cell adhesion suggests that 
Fyn acts primarily at the adhesion complex itself, phosphorylating target proteins to 
either increase or decrease the stability of the junctions (Calautti et al, 2002, Piedra et al, 
2003).  Therefore, we expected that Dasatinib treatment would initially act at the 
adherens junction, increasing the stability of the adhesion and activating signaling 
cascades that resulted in F-actin upregulation.  This, however, is not what we observed.  
Instead, following pretreatment with the ROCK inhibitor Y27632 the cells no longer 
formed aggregates in the cell culture plate upon Dasatinib exposure, suggesting increased 
F-actin was necessary for the increase in cell-cell adhesion (Figure 41).  To test whether 
adherens junction formation or F-actin stability was initiated before junctional adhesion, 
we pretreated the cells with Cytochalasin D, a mycotoxin that prevents actin 
polymerization.  This pretreatment blocked Dasatinib’s ability to increase cell-cell 
adhesion in the HaCaT-Ras cells, further suggesting that actin polymerization was 
required for formation of cell-cell adhesive structures (Figure 45).  We then cultured the 
cells in low Ca+2 media, cell culture conditions that block the formation of Ca+2-
dependent cadherin-based adhesions such as adherens junctions and desmosomes.  
Culture in low Ca+2 conditions did not prevent the Dasatinib-induced increase in F-actin, 
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indicating that loss of cell-cell adhesion was not sufficient to block the polymerization of 
cortical F-actin (Figure 46).  Together these results suggest that the increase in cell-cell 
adhesion through the adherens junction by Dasatinib first required or was being driven by 
polymerization of the actin cytoskeleton.  Increased cell-cell adhesion, in turn, should 
theoretically decrease the ability of cells with elevated Fyn to detach from surrounding 
cells, blocking their migratory potential.  Additionally, these findings provide 
mechanistic information on how Dasatinib induces a pronounced cell-clumping 
phenotype, an observation previously made in other cell types but never characterized 
(Chan et al, 2012).     
 
7.6 Treatment with Dasatinib Reduces Total Tumor Burden Following Extensive 
UV Exposure 
 
 
Twenty-three clinical trials are currently in progress or just concluded (clinicaltrials.gov) 
to study the results of Dasatinib treatment in solid tumors, including melanoma, prostate 
cancer, breast, head and neck and colorectal cancers (Montero et al, 2011).  Previous 
investigators have found that transgenic expression of active Fyn in a murine epidermis 
induced the formation of keratotic tumors and actinic keratoses that progressed to cSCCs 
(Zhao et al, 2009).  Surveys of human cSCCs have also shown increased SFK activity 
through all layers of the tumor (Ayli et al, 2008).  Due to the lack of targeted therapies for 
cSCC and our findings concerning Fyn’s role in keratinocyte migration and the ability to 
increase cell-cell adhesion following Fyn inhibition, we chose to investigate Dasatinib’s 
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ability to prevent cutaneous tumorigenesis in a UVB mouse model.  Dasatinib treatment 
significantly reduced total tumor burden following extensive UVB exposure, but did not 
alter tumor size or the general tumor histopathology (Figures 49 & 52), adherens junction 
makeup or overall keratinocyte acantholysis (data not shown).  However, the tumors were 
analyzed one week after the last Dasatinib exposure, allowing sufficient time for adhesive 
structures to be re-established between tumor keratinocytes.  Our results are consistent 
with the ability of oral AZD0530, a SFK inhibitor, to reduce chemically induced mouse 
skin tumors when given by oral gavage (Serrels et al, 2009).  Therefore, the use of 
Dasatinib as a topical therapy may be an effective method to prevent the formation of 
skin tumors following UV exposure.  This treatment is particularly appealing, as a topical 
therapy is cost effective as well as localized to the site of tumor formation, and requires a 
lower overall dose, resulting in fewer side effects.   
 
7.7 Significance: Fyn as a Novel Target in cSCCs 
 
In this work we have identified potential transcription factors driving Fyn expression in 
Ras-transformed keratinocytes, as well as shown that increased Fyn activity is sufficient 
to induce EMT in keratinocytes.  Inhibition of Fyn activity, either using siRNA or the 
therapeutic Dasatinib, released Rho inhibition and resulted in rapid upregulation of the F-
actin cytoskeleton, increasing cell-cell adhesion through the adherens junction and 
blocking the cell’s migratory capacity.  Additionally, Dasatinib treatment following UVB 
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exposure decreased UV-induced tumorigenesis in vivo.   These findings suggest that Fyn 
may be an effective therapeutic target in the treatment of cSCC, as it may reduce the 
danger of cellular invasion and migration, risk factors that dramatically reduce the 
predicted disease free survival rate among patients.    
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Figure 56: Mechanism of Cell-Cell Adhesion Following Fyn Inhibition 
Increased Fyn activity, potentially through an increase in Ras signaling, induces 
keratinocytes to undergo EMT and inhibits Rho activity.  Dasatinib treatment 
inhibits Fyn, releasing this inhibition of Rho to increase the stable F-actin 
cytoskeleton.  This increase in F-actin stabilizes the formation of adherens 
junctions, resulting in increased cell-cell adhesion and decreased migration.  
Inhibition of SFK activity using Dasatinib also results in decreased total tumor 
burden following extensive UV exposure in a murine model.   
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